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Abstract: Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The two 
main forms of IBD are Crohn's disease and ulcerative colitis. According to the recent concept the disease is caused by a combination of 
factors, including genetics, immune dysregulation, barrier dysfunction and the change in microbial flora. Environmental factors, such as 
changes in diet, antibiotic use, smoking or improved domestic hygiene (e.g. eradication of intestinal helminths) probably contribute to the 
development and increased prevalence of IBD. Dysregulation of mucosal immunity in IBD causes an overproduction of inflammatory cy-
tokines which resulted in uncontrolled intestinal inflammation. Based on extensive research over the last decade, besides the conventional 
therapy, there are several novel pathways and specific targets, on which focus new therapeutics. New therapeutics aim 1./ to correct ge-
netic susceptibility by stimulating NOD2 expression, TLR3 signaling or inhibition of TLR4 pathway, 2./ to restore the immune dysregu-
lation by inhibition of pro-inflammatory cytokines (TNF-, IL-6, IL-13, IL-17, IL-18, IL-21), Th1 polarisation (IL-2, IL-12, IL-23, IFN-
), T-cell activation, leukocyte adhesion, as well as by immunostimulation (GM-CSF, G-CSF) and anti-inflammatory cytokines (IL-10, 
IL-11, IFN--1a), 3./ to restore mucosal barrier function and stimulate mucosal healing by different growth factors, such as GH, EGF, 
KGF, TGF-, VEGF, 4./ to restore the normal bacterial flora by antibiotics, probiotics. However, in spite of these numerous potential tar-
gets, the true value and clinical significance of most of the new biologics and molecules are not clear yet. 
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1. INTRODUCTION 
 Inflammatory bowel disease (IBD) is a chronic and relapsing 
inflammatory condition of the gastrointestinal (GI) tract. The two 
main forms of IBD are Crohn's disease (CD) and ulcerative colitis 
(UC), though other forms are also known, which are also classified 
as not typical IBD (e.g. collagenous colitis, lymphocytic colitis). 
 The cause of IBD is not exactly known. The recent consensus is 
that IBDs are initiated and perpetuated by an impaired immune 
response against the gut microbiota in genetically susceptible indi-
viduals [1, 2] and the disease is caused by a combination of factors, 
including genetics, immune dysregulation, barrier dysfunction, 
change in microbial flora and environmental influences (see re-
views [3-7]). 
 Though UC and CD share some common clinical symptoms, 
the two diseases possess very distinct features. First of all, the loca-
tion of the inflammation is different; CD can develop at any part of 
the intestine, though most of the cases are localized at the terminal 
ileum. In contrast, in UC the inflammatory process is restricted to 
the colon and the rectum. Moreover, the pathological changes in 
CD affect the whole bowel wall and manifested as transmural le-
sions, while in UC the inflammation is restricted to the mucosa 
(epithelial lining of the gut). Also differences in immunological 
response of intestinal mucosa have been described. CD is associ-
ated with the activation of types 1 and 17 T-helper (Th) cells in 
response to interleukin (IL)-12, IL-18, IL-23 and transforming 
growth factor  (TGF-), and activation of these cells results in 
increased secretion of the pro-inflammatory cytokines IL-2, IL-17, 
interferon (IFN)- and TNF- [8, 9]. In patients with UC the mu-
cosal inflammation of the colon is mainly associated with a Th2 cell 
activation mediated by IL-4, IL-5 and IL-13 that results in an in-
creased level of IL-13 [10, 11]. However, in both cases T-cells are 
also activated by direct contact with antigens [12]. 
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 As regards the clinical symptoms, body weight loss and fever 
are more common in CD. Ulcerations, granulomas, and bowel fistu-
las are characteristic for CD, in contrast, UC affects the mucosa in a 
continuous manner. Moreover, smoking was found to be protective 
against UC and might improve its course, but seems to increase the 
risk of developing CD and worsens its course [13]. 
 On the other hand, extra-intestinal manifestations (liver prob-
lems, arthritis, skin manifestations and eye problems) can develop 
in both CD and UC. Some patients have an extra-intestinal manifes-
tation as their first symptom of the disease, while they still have 
only mild gastrointestinal manifestation, or none at all. Anemia is 
the most prevalent extraintestinal complication of both IBDs [14, 
15]. 
 The chronic inflammation of the gut causes wide-ranging clini-
cal symptoms in both forms, like nausea, diarrhea (which is often 
porridge-like in CD, while mucus-like with blood in UC) or 
abdominal pain [16, 17]. 
 UC or CD patients have increased risk for colorectal carcinoma 
(CRC). Patients with UC and Crohn’s ileocolitis have an elevated 
risk of developing colon cancer, while patients with CD and enteri-
tis have an elevated risk of developing small-bowel cancer [18, 19]. 
The cumulative risk for developing colorectal cancer was 8% at 22 
years from onset of symptoms for Crohn’s colitis and 7% at 20 
years from onset of symptoms for UC, as it accounts for one in six 
of all deaths in IBD patients [20]. 
 The high incidence and prevalence of IBD (worldwide inci-
dence of UC and CD varies between 0.5-24.5 and 0.1-16 individu-
als per 100.000 inhabitants, respectively) [21], and the costs of the 
long-term and only symptomatic treatment of the patients place a 
significant burden on the healthcare system: the expenses exceed 
1.7 billion dollars per year in the United States [22], and are in 
similar range in European countries. 
 Although in the last decade our knowledge about the pathome-
chanism of IBDs greatly expanded (which is also clearly demon-
strated by the continuously rising number of publications in this 
field), and several important milestones have been achieved, dis-
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tinction between causing events and secondary consequences is still 
challenging. 
 The aim of this review is to shortly summarize the current 
knowledge and newest findings in the pathomechanism of IBD as 
well as to overview some of the therapeutic targets and strategies 
(convential and novel ones) for the treatment of IBD. 
2. PATHOMECHANISM 
2.1. Genetic Susceptibility 
 The familial aggregation of IBD has already been observed 
several decades ago and studies conducted on twins also confirmed 
the importance of hereditary factors in the pathogenesis of IBD 
(especially for CD), though they also highlighted the role of envi-
ronmental trigger factors [23-27]. 
 Genome wide association studies (GWASs) performed during 
recent years provided better insight into the genetic background of 
IBD. They revealed 163 genomic susceptibility loci associated with 
IBD so far, 110 with both disease phenotypes, and further 30 and 
23 associated selectively either with CD or UC, respectively [28, 
29]. The considerable overlap of susceptibility loci in CD and UC 
indicates that these two IBD phenotypes share several common 
factors in their pathogenesis. 
 Although the exact functional role of several IBD susceptibility 
genes still remains to be established, many of them are associated 
with host immune functions, including both innate and adaptive 
immunity. 
 The first susceptibility gene identified for CD was NOD2/ 
CARD15, which brought the role of innate immunity and pattern 
recognition receptors (PRRs) in the pathogenesis of IBD to the fore. 
As described in the next section, PRRs play an essential role in the 
host microbial interaction by sensing conserved microbial structures 
(pathogen-associated molecular patterns, PAMPs). Binding of 
PAMPs results in the activation of multiple signaling pathways 
including nuclear factor-B (NF-B) and mitogen activated protein 
kinases (MAPKs), which in turn induce the production of inflam-
matory mediators and also initiate multiple cellular processes, in-
cluding cell proliferation and differentiation [30-32]. NOD2, a 
member of the nucleotide-binding oligomerization domain (NOD)-
like receptor (NLR) family, recognizes muramyl dipeptide (MDP), 
a component of peptidoglycan (PGN) in nearly all bacteria [30]. 
The three most common NOD2 mutations, a frame-shift insertion 
mutation (3020insC) and two missense mutations (R702W and 
G908R) result in impaired recognition of MDP and in loss of NF-
B activation in response to lipopolysaccharide (LPS) and PGN 
[33-36]. Several groups confirmed the association of NOD2 with 
CD, but interestingly, no such connection was found in Japanese 
individuals [37]. This is in line with other findings (see below) 
indicating that genetic determinants can differ significantly between 
populations. 
 In the last 2 decades several other PRR genes have been associ-
ated with IBD. A british group reported that a complex inser-
tion/deletion polymorphism in NOD1/CARD4 (+32656) may con-
tribute to the development of IBD and can result earlier onset and 
extra-intestinal manifestations [38], but other groups could not re-
produce these findings in German [39], Scottish and Swedish pa-
tients [40]. 
 Single nucleotide polymorphisms (SNPs) in Toll-like receptor 
(TLR) TLR1 and TLR2 genes (R80T and R753Q) were found to 
increase the risk of pancolitis in UC, but did not increase the sus-
ceptibility to disease development [41]. 
 Several studies have been conducted to identify the role of the 
TLR4 gene in the pathogenesis of IBD, but similarly to NOD2, 
substantial heterogeneity was found between populations. The 
D299G SNP was associated with IBD in Belgian [42], German [43, 
44], Greek [45] or Australian [46], but not in Southern Italian [47], 
Hungarian [48] or New Zealand patients [49, 50]. Nevertheless, 
meta-analyses have provided evidences for an association between 
D299G and IBD [49, 50]. Similar discrepancies were observed with 
the T399I SNP, because significantly increased allele and carrier 
frequencies for this mutation were observed in patients with UC in 
a German cohort [44], while other groups could not demonstrate 
such association [45, 47, 49, 50]. 
 The importance of PRR mutations in the development of IBD is 
further supported by the findings that a TLR9 polymorphism (-
1237T/C) was significantly higher in patients with CD [50], while 
polymorphism in the CARD9 gene (rs10870077), which encodes an 
adaptor molecule of PRR signaling, was associated with both CD 
and UC [51, 52]. 
 Beside PRR genes GWASs have identified several other sus-
ceptibility genes, which has led to better understanding of the path-
omechanism. The identification of IBD associated polymorphisms 
in autophagy-related 16-like 1 (ATG16L1) and immunity-related 
GTPase family M protein (IRGM) genes has revealed that impaired 
autophagy, and the consequent defects in innate immune responses 
to intracellular pathogens may be critical components of the chronic 
inflammation in IBD [53-56]. IBD associated alterations in X-box-
binding protein 1 (XBP1) and orosomucoid-like 3 (ORMDL3) 
genes imply that changes in the unfolded protein response (UPR) 
and the failure to manage endoplasmic reticulum stress may also 
contribute to the pathogenesis, for example due to increased apop-
tosis of Paneth cells [57, 58]. Mutations in the mucin genes (e.g. 
MUC1, MUC19) or in the prostaglandin receptor EP4 gene 
(PTGER4) can lead to impaired mucosal barrier functions [51, 59], 
while genetic variations in the IL18RAP [52], IL23R [60, 61], 
STAT3 [62] or SMAD3 [51] genes highlight the importance of 
failures in the adaptive immune responses in IBD. 
2.2. Immune Dysregulation 
 The intestinal mucosa is continuously exposed to a vast number 
of antigens (both dietary and microbial), which are recognized by 
the mucosal immune system. Under normal circumstances it distin-
guishes between beneficial and pathogenic microbes - it tolerates 
normal commensal bacteria, while eliminates invading pathogens. 
Today it is widely accepted that abnormal immune regulation is a 
key factor in the pathomechanism of IBD and alterations in both 
innate and adaptive immunity have been observed. This section 
shortly overviews the key players of the immune system and their 
contribution to IBD. For more comprehensive recent immunologi-
cal reviews see e.g. [63-66]. 
 The pattern recognition receptors (PPRs) play a key role in the 
bacteria-host interaction. These innate immune receptors are ex-
pressed by different cells of the intestinal mucosa (like dendritic 
cells (DCs), macrophages and intestinal epithelial cells (IECs)), and 
recognize conserved microbial structures (PAMPs). Probably the 
best-characterized family of PRRs are the Toll-like receptors 
(TLRs). This family comprises 13 members in mammals, ten in 
humans (TLR1-10) and 12 in mice (TLR1-9, TLR11-13) [67]. Most 
TLRs (TLR1, 2, 4, 5, 6 and 11) are localized on the cell surface, 
where they recognize mainly bacterial cell wall components (LPS 
of Gram negative bacteria by TLR4, lipoproteins from Gram-
positive bacteria by TLR1, 2 and 6, flagellin by TLR5), while some 
members in this family are localized intracellularly in the en-
dosomes (TLR3, 7, 8 and 9) and recognize viral or bacterial nucleic 
acids [68, 69]. 
 The family of NOD-like receptors (NLRs) includes 23 members 
in humans and 34 in mice [31, 69]. These cytoplasmic receptors 
contain a leucine-rich repeats (LRR) domain, which senses bacterial 
ligands, a central NOD domain (also called NATCH domain) re-
quired for activation and an N-terminal effector domain that medi-
ates interactions with other signaling proteins. Based on the effector 
domain five subfamilies can be distinguished, these are NLRA (also 
called CIITA, which contains an acidic domain), NLRB (or NAIP, 
Gut Inflammation: Current Update on Pathophysiology Current Pharmaceutical Design, 2014, Vol. 20, No. 00    3 
which contains baculovirus inhibitor repeats (BIR)), NLRC (or 
NOD, which possesses a caspase recruitment domain (CARD)), 
NLRP (or NALP, contains a pyrin domain (PYD)) and NLRX (con-
tains an unidentified domain) [30, 69, 70]. 
 Further PRRs are the retinoic acid-inducible gene-I (RIG-I)-like 
receptors (RLRs), like RIG-I, MDA5 and LGP-2, which are also 
intracellularly localized and sense primarily viral RNAs [71], and 
the C-type lectin receptors (CLRs), including Dectin-1, Dectin-2, 
mannose receptor, C-type lectin receptor DC-SIGN and Mincle, 
which play an essential role in antifungal immunity [72, 73]. 
 As mentioned above, PRRs are expressed by various cells in the 
intestinal mucosa and their activation modulates inflammatory 
processes at various levels. At first, they regulate the barrier func-
tion of the mucosa, which is the front line of defense against intes-
tinal pathogens. The damage of IECs and their barrier function 
leads to an increased penetration of the microbes in the gut wall, 
which in turn activates immune cells and causes inflammation. 
Several studies demonstrate barrier disturbance in both animal coli-
tis models and in patients with CD and UC [74-77]. In IBD IEC 
permeability increases both transcellularly (in which TNF- has a 
major role) [78] and paracellularly via junctional complexes. For 
instance, an impaired tight junction sealing due to upregulation of 
claudin 2 and downregulation of claudin 5, claudin 8 and occludin 
was reported in patients with active CD [79]. PRRs are involved in 
the modulation of epithelial integrity. Activation of TLR2 enhances 
the transepithelial resistance in vitro (through redistribution of the 
tight junction protein ZO-1) and increases tight junction-associated 
IEC barrier integrity in vivo [80, 81], and recent evidence suggest 
that NOD2 potentiates the TLR2-induced improvement of mucosal 
barrier [82]. Beside TLR2 also TLR9 has been shown to enhance 
transepithelial resistance [83], while the action of TLR4 is still not 
clear, since both improvement and disruption of the mucosal barrier 
have been described upon stimulation with LPS [82, 84]. 
 PRRs are also able to enhance mucosal barrier functions via 
stimulating the secretion of antimicrobial peptides (AMPs), like 
cathelicidin and defensins. These peptides are secreted into the gut 
lumen by leukocytes and epithelial cells and regulate host microbial 
interaction and the composition of the commensal microbiota [74, 
85]. The expression of -defensins by Paneth cells is associated 
with NOD2 signaling [86] and decreased -defensin production was 
observed in CD patients with NOD2 mutations [87, 88] although it 
has also been raised that reduced -defensin production is only the 
consequence, and not the cause of the inflammation [89]. Beside 
regulating the -defensin production, PRRs stimulate also the secre-
tion of other AMPs. The activation of TLR4- and TLR2 increased 
-defensin-2 expression by human IECs [90] and the expression of 
cathelicidin by mucosal macrophages was connected with TLR9 
signaling in mice [91]. Taking the manifold effects of PRRs on 
AMP production into consideration, it is not unexpected that PRR 
signaling can also shape the structure of the gut microbial commu-
nity. For example in TLR2 KO mice the proportion of Firmicutes 
and Proteobacteria was significantly higher and lower, respec-
tively, in the gut microbiota [92], while NLRP6 deficiency was 
associated with increased representation of Prevotellaceae [93]. 
Hence, not only microbes can influence the host immune response 
via PRRs, but vice versa, PRRs can also influence the make up of 
the microbiota and control the load of commensal bacteria. 
 The healing of the intestinal mucosa in case of epithelial injury 
is essential to restore barrier functions. The controlled migration, 
proliferation and functional differentiation of IECs is regulated by 
various growth factors (including epithelial growth factor (EGF), 
TGF-, TGF- and fibroblast growth factor (FGF)), chemokines, 
regulatory cytokines (e.g. IL-6, IL-22) and trefoil peptides [94]. 
Several results suggest that epithelial restitution is influenced by 
PRRs. TLR2 induces gap junctional intercellular communication 
via connexin-43, and controls IEC restitution during acute and 
chronic inflammatory damage [95]. Similarly to TLR2, TLR4 is 
also likely to improve mucosal healing. Decreased epithelial prolif-
eration was found in TLR4 deficient mice [96] and antibody di-
rected against TLR4 impaired mucosal healing due to reduced ex-
pression of cyclooxygenase-2, prostaglandin E2 (PGE2) and am-
phiregulin [97]. Beside TLRs also NLRs are able to modulate the 
regeneration of the IECs. NLRP3 (also known as NALP3 or 
cryopyrin), which is one of the best-characterized NLRPs, recruits 
ASC (apoptosis-associated speck-like protein) and pro-caspase-1 
into a large protein complex (inflammasome) to mediate the secre-
tion of IL-1 and IL-18 [66]. Zaki et al. [98] demonstrated that 
NLRP3-, ASC- and caspase-1 KO mice are highly susceptible to 
dextran sulfate sodium (DSS) colitis, which is due to the decreased 
maturation and secretion of IL-18, and the consequent reduction of 
epithelial regeneration. 
 Beside regulating mucosal barrier functions, PRRs on DCs and 
macrophages are key factors in innate immunity. 
 DCs express a wide range of PRRs and interpret microbial pat-
terns to direct other immune cells towards immunity or tolerance. 
They are able to sample luminal antigens directly by forming tran-
sepithelial dendrites [99]. Upon encounter with pathogens, DCs 
undergo rapid maturation characterized by upregulated expression 
of major histocompatibility complex (MHC) and co-stimulatory 
molecules (like CD80, CD86, CD40) and production of pro-
inflammatory cytokines (IL-1, IL-6, IL-12, IL-23, TNF-). Then 
they migrate to the draining lymph nodes, where promote the pro-
liferation and differentiation of naïve CD4 T-cells to Th1, Th2 or 
Th17 subsets. On the other hand, DCs are also important for the 
maintenance of homeostasis and tolerance against the commensal 
microbes via the production of anti-inflammatory cytokines such as 
IL-10 and TGF- and the production of tolerogenic regulatory T 
(Treg) cells [63, 100, 101]. 
 Several studies demonstrate the active involvement of DC in 
the pathogenesis of IBD. The number of DCs expressing the matu-
ration markers CD80, CD83, CD86 and CD40 is elevated in CD 
and UC [102-105]. DCs express also higher levels of TLR2 and 
TLR4 [102] and accordingly, show exaggerated response to LPS in 
IBD [106]. This may result in false recognition of commensal bac-
teria and induction of pro-inflammatory immune responses. Beside 
secreting higher amounts of pro-inflammatory cytokines, DCs are 
also less able to induce tolerogenic Foxp3
+
 Treg cells in CD [107]. 
 The role of intestinal macrophages in IBD has also been inten-
sively studied [63]. Similarly to DCs, macrophages also present 
antigens to T-cells and induce their differentiation to pro- or anti-
inflammatory subsets [108, 109]. M1 macrophages produce pro-
inflammatory cytokines TNF-, IL-12 and IL-23, and promote a 
polarized Th1 response, while M2 macrophages are characterized 
by production of IL-10 [109]. Thus, M2 macrophages may have 
important role in maintaining intestinal homeostasis and alterations 
in the levels of macrophages and their cytokines can contribute to 
the pathomechanism of colitis in animal models and in IBD. Ac-
cordingly, Smith et al. [110] found different cytokine profiles re-
leased by macrophages in healthy controls and CD patients after 
stimulation with heat-killed Escherichia coli or with the TLR2 
ligand Pam3CSK4. 
 It is noteworthy, that Kamada et al. [111] observed the infiltra-
tion of unique CD14+ intestinal macrophages in the mucosa of CD 
patients at both inflamed and non-inflamed sites. These macro-
phages produced larger amounts of pro-inflammatory cytokines, 
such as IL-6, IL-23 and TNF-, than typical intestinal resident 
macrophages, and the authors raised the possibility that CD14+ 
macrophages may play a key role in the predominance of Th1 im-
mune response found in CD [111]. 
 The role of macrophage migration inhibitory factor (MIF), an 
other pro-inflammatory cytokine originating from both T-cells, 
innate immune cells and epithelial and endothelial cells in the path-
omechanism of IBD is emerging [112, 113]. MIF promotes the 
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recognition of LPS and Gram-negative bacteria by upregulating the 
basal expression of TLR4 in the macrophages, thus serves as a key 
factor in the initiation of innate immune response [114]. The release 
of MIF stimulates the release of inflammatory cytokines, potenti-
ates the recruitment of neutrophils to the inflammatory site and 
triggers metalloprotease (e.g. MMP-13) expression, leading to in-
flammation and tissue damage [112]. The expression of MIF was 
increased in DSS-induced colitis and administration of anti-MIF 
antibody significantly improved the DSS-induced symptoms [115]. 
Moreover, the levels of MIF in the sera of UC patients were signifi-
cantly higher [116], which suggests that anti-MIF therapy may be a 
new therapeutic approach in IBD. Since increased MIF-expression 
is also associated with tumorigenesis [117], it is tempting to specu-
late that inhibition of MIF may also reduce the risk of colon cancer 
related to chronic inflammation. 
 As depicted above, the activation of PRRs expressed on innate 
immune cells and the consequent release of inflammatory cytokines 
results in different T-cell pattern. In CD mainly the Th1 cytokines 
(IL-12, TNF-, IFN-), while in UC predominantly Th2-associated 
cytokines (like IL-5 and IL-13) are dominating [118-120], and rec-
ognition of the importance of these cytokines led to the develop-
ment of anti-cytokine biologic agents in the therapy of IBD. How-
ever, it has to be emphasized that the cytokine profile of these dis-
eases is much more complex and even individual cytokines may 
possess diverse or opposing action in different clinical and immu-
nological settings [64]. 
 Furthermore, the recent discovery of the Th17 lineage has 
raised a new paradigm. Th17 cells differentiate from naïve CD4 T-
cells, which process is induced and regulated by various cytokines, 
like IL-1, IL-6, IL-21, IL-23 and TGF- [121]. It has been re-
vealed that Th17 cells, producing IL-17 and other pro-inflammatory 
cytokines play an essential role in the development of colitis in both 
mice and humans [122-124]. 
 The activation of PRRs (both TLRs and NLRs) by the intestinal 
microbiota is essential for the development of Th17 cells, which is 
clearly demonstrated by the marked reduction of the Th17 cell 
number in germ-free mice [125, 126]. Accordingly, stimulation of 
TLR5 on lamina propria DCs promoted the differentiation of Th17 
cells [127], while TLR9-deficient mice had decreased number of 
lamina propria Th17 cells [128]. Moreover, the stimulation of DCs 
with MDP has been shown to enhance NOD2-mediated production 
of IL-1 and IL-23, which in turn promoted the IL-17 production 
by memory T-cells [129]. These results highlight the importance of 
PRRs also for adaptive immunity. In addition, although originally 
PRRs were thought to regulate innate immunity and only indirectly 
the adaptive responses, it turned out that also T- and B-cells express 
PRRs, and TLR or NLR agonists are able to directly influence their 
functions [32, 130, 131]. 
 In summary, disruption of the mucosal barrier, increased and 
altered activation of DCs and macrophages, impaired balance be-
tween pro- and anti-inflammatory cytokines and polarisation of the 
adaptive immune response towards the effector T-cells all contrib-
ute to the pathomechanism of IBD, and PRRs are an important link 
between the participants of this complex system. 
2.3. The Microbiota 
 The human gut is inhabited by ~ 100 trillion bacteria, which can 
consist of more than 1000 species overall and at least 160 species in 
each individual [132]. This indigenous bacterial community (the 
microbiota) is influenced by several factors (like diet, age or health 
status) and varies between individuals, although mainly only at the 
levels of strains and species, while most of the bacteria are mem-
bers of the Bacteroidetes and Firmicutes phyla [133, 134]. The 
microbiota plays a fundamental role in energy metabolism and im-
munity, however, its role has also been implicated in several dis-
eases, e.g. obesity, insulin resistance and IBDs (recently reviewed 
e.g. by [135-137]). 
 In the last decades considerable efforts have been made to iden-
tify a specific pathogen in IBD, and some bacteria (e.g. Mycobacte-
rium avium spp. paratuberculosis or adherent-invasive Escherichia 
coli (AIEC)) have been proposed as causative agents, mainly in CD 
[138-140]. Moreover, various clinical studies were conducted to 
analyze the potential therapeutic effect of different antibacterial 
regimens (usually with the agents clarithromycin, metronidazole, 
ciprofloxacin or rifaximin) (see section 3.4.), but the results are 
conflicting [141, 142]. Now it is generally assumed, that instead of 
one (or few) distinct pathogen(s) an altered composition of gut 
flora, resulting in dysbiosis, and an overactive immune response 
may lead to chronic intestinal inflammation [143]. 
 It is well established that the microbiota in IBD patients differs 
significantly from that of healthy people. One main difference is the 
decreased representation of the Firmicutes phylum. A reduction of 
the Clostridium leptum and coccoides groups (also known as Clos-
tridium cluster IV and XIVa, respectively), and in particular the 
decreased amount of Faecalibacterium prausnitzii was observed by 
several groups [144-148]. Indigenous Clostridia may possess anti-
inflammatory properties by inducing IL-10 expressing Foxp3
+
 
CD4
+
 Treg cells in the colon [149]. Moreover, the loss of these 
bacteria may result in a decreased butyrate production, which is one 
of the most important bacterial products in the gut and exerts vari-
ous anti-inflammatory effects via regulating the migration of neu-
trophils, inhibiting the production of pro-inflammatory cytokines 
and increasing the expression of tight junction proteins in colon 
epithelia [136, 150]. 
 Another important genus in this phylum is the Lactobacillus, 
which contains several probiotic strains. Some of them (e.g. the 
Lactobacillus rhamnosus GG strain) may possess beneficial effects 
in IBD [151] and recent evidences indicate that Lactobacillus sali-
varius Ls33 is able to inhibit experimentally induced colitis in a 
NOD2-dependent manner [152]. Furthermore, von Schillde et al. 
identified a Lactobacillus paracasei prtP-encoded protease named 
lactocepin, which degrades the pro-inflammatory chemokine IP-10 
(interferon gamma-induced protein 10) and consequently alleviates 
colonic inflammation [153]. Thus, a reduced amount of Lactobacil-
lus may contribute to the pathogenesis of IBD. Indeed, such altera-
tions in the microbiota were observed by several authors [93, 145], 
though increased amounts [144] or no change of Lactobacillus lev-
els [147] have also been reported. 
 Alterations in the Bacteroidetes phylum are also likely to con-
tribute to the chronic inflammation. An increased representation of 
the Prevotellaceae has been documented in IBD patients [154, 155] 
and recently also in the intestines of mice with an impaired innate 
immunity [93]. It is assumed that these bacteria are colitogenic via 
producing sulfatases, that degrade mucus oligosaccharides and 
disrupt mucosal barrier function [156]. 
 In contrast, Bacteroides fragilis is supposed to exert anti-
inflammatory effects. Its Polysaccharide A (PSA) component has 
been shown to inhibit Helicobacter hepaticus-induced experimental 
colitis in mice [157] and to directly induce the anti-inflammatory 
function of Foxp3
+
 Treg cells by acting on TLR2 [158]. Although 
early observations suggested a higher abundance of Bacteroides 
fragilis in IBD patients [159], recent studies found lower levels of 
this commensal [146, 147]. 
 Similarly to Lactobacilli, Bifidobacteria from the Actinobacte-
ria phylum also contain several probiotic strains and exert anti-
inflammatory effects. Bifidobacteria had beneficial effect in both 
animal models [160] and in patients with UC and CD [161-163], 
while lower count of Bifidobacteria was measured in IBD [147]. 
One potential protective mechanism is the activation of Tregs, as it 
has been observed in the case of Clostridia and B. fragilis (see 
above). The probiotic Bifidobacterium breve induced IL-10-
producing Treg type 1 cells by activating intestinal CD103+ den-
dritic cells via the TLR2/MyD88 pathway [164]. Another strain, 
Gut Inflammation: Current Update on Pathophysiology Current Pharmaceutical Design, 2014, Vol. 20, No. 00    5 
Bifidobacterium lactis significantly decreased the colonic expres-
sion of various pro-inflammatory, dendritic and T-cell markers, like 
IL-6, TNF-, COX-2, CD40-L or IFN- in mice [160]. 
 In summary, there is growing evidence that an imbalance be-
tween colitogenic (e.g. AIEC) and tolerogenic bacteria (like Clos-
tridia, Lactobacilli and Bifidobacteria) has a major role in the path-
omechanism of IBD. Colitogenic bacteria can damage the epithelial 
barrier functions either directly or via producing toxins. For in-
stance AIEC strain LF82 disrupts the tight junction protein zonula 
occludens-1 [165] and through binding to the cell adhesion mole-
cule CEACAM 6 can lead to abnormal expression of claudin 2 
[166], while enteropathogenic Escherichia coli (EPEC) induces 
epithelial cell apoptosis by producing a bacterial toxin called cycle 
inhibiting factor [167]. Both results in an increased intestinal per-
meability, which permits the penetration of luminal antigens and 
microbes, that can stimulate pro-inflammatory responses. 
 However, the altered microbial flora can also induce inflamma-
tion indirectly, via reduced production of anti-inflammatory bacte-
rial metabolites, like butyrate and other short-chain fatty acids (see 
above) [136] or via an altered metabolism of bile acids. Primary 
bile acids cholic acid and chenodeoxycholic acid are transformed 
by intestinal bacteria to their secondary forms, deoxycholic acid 
and lithocholic acid, which can disrupt intestinal barrier functions 
[168, 169]. The recent results of Duboc et al. provide direct evi-
dence of the connection between dysbiosis, bile acid dysmetabolism 
and chronic colonic inflammation [144]. They found a marked de-
crease in bacteria of the Firmicutes phylum and altered levels of 
secondary and conjugated bile acids in the faeces of patients with 
IBD. 
2.4. Environmental Factors 
 Environmental factors may also play a role in the pathogenesis 
of IBD. As mentioned earlier, the composition of the microbiota is 
substantially influenced by diet and other life style factors [170, 
171], and accordingly, dietary changes may contribute to the path-
omechanism of IBD. Indeed, it was demonstrated that consumption 
of a diet high in saturated (milk derived)-fat promoted colitis in IL-
10 knock out mice [172]. The triggering factor was presumably the 
increased taurine-conjugation of bile acids, which increased the 
availability of organic sulfur and the amount of the sulfite-reducing 
microbe Bilophila wadsworthia, which in turn induced Th1 immune 
responses. Moreover, Kim et al. [173] reported that high fat diet 
altered the microbiota leading to an increased lumenal LPS content 
in the colon, which increased intestinal permeability and induced 
inflammation through a TLR4 signaling pathway. 
 In addition, vitamin D deficiency [174], as well as active and 
passive tobacco smoking [13, 175], air pollution [176] or improved 
domestic hygiene and sanitation [177] are additional factors that 
may modify the homeostasis of the intestinal mucosa. The observa-
tions, that IBD is common in Western countries, while uncommon 
in less developed areas, raised the intriguing hypothesis that im-
proved hygiene and the consequent loss of routine exposure to 
parasitic worms (helminths) may play an important role in the path-
omechanism of IBD [178]. 
 Helminth infections may have several beneficial effects on the 
immune system (reviewed by [179, 180]). They induce the forma-
tion of regulatory DCs, regulatory Treg cells and the production of 
anti-inflammatory cytokines (IL-10, TGF-), while decreasing the 
formation of effector T-cells and pro-inflammatory cytokines (like 
IFN-, IL-17 or IL-12/23). Moreover, they seem to alter the compo-
sition of the microbiota and promote the growth of probiotic Lacto-
bacillaceae [181]. 
3. THERAPY 
 The traditional therapeutic concept of CD is based on the so-
called "step-up" approach: less toxic drugs (but often less effect- 
 
tive), are given in mild disease, whereas more effective (but poten-
tially more toxic) agents are given in severe disease or in patients 
who are unresponsive to first-line therapy. Common conventional 
medications currently start with 5-aminosalicylic acid drugs, 
corticosteroids (prednisolone, methylprednisolone, budesonide) for 
UC as well as CD. Immunosuppressive agents such as azathioprine 
and 6-mercaptopurine were shown to be effective in both CD and 
UC, while methotrexate proved to be effective as a steroid-sparing 
agent in CD. On the other hand, cyclosporine induced a pronounced 
therapeutic effect in severe, active UC [182, 183, 184]. 
 A milestone in the therapy of CD was the introduction of in-
fliximab, the first monoclonal antibody against TNF-, proved to be 
effective in induction of remission in CD patients who had been 
refractory to other therapeutic agents [185]. Later, it was demon-
strated that both adalimumab, and certolizumab, monoclonal anti-
bodies against TNF-, maintained the clinical remission [186, 187]. 
Surprisingly, etanercept (another anti-TNF- agent, that fuses the 
TNF receptor to the constant end of the IgG1 antibody) failed to 
exert similar beneficial effect in CD [183, 188]. 
 The more effective biological therapies are usually considered 
as a last option and only in case of refractory diseases, because they 
often cause severe adverse effects [189, 190]. This strategy is rec-
ommended by current guidelines [191]. 
 However, the natural course of the disease is not likely to be 
modified by conventional treatment [192]. Since anti-TNF- ther-
apy can induce and maintain clinical remission and mucosal heal-
ing, early administration of anti-TNF- biological agents may pre-
vent late complications [193]. Consequently, the question has been 
raised recently: whether to maintain or to reverse the traditional 
therapeutic pyramid [194]. On the other hand, it also has to be kept 
in mind that majority of CDs have benign course and immune 
modulators and biologics have severe adverse effects, that may 
result in increased risk of infections and malignant diseases 
(lymphoma) [195]. Consequently, treatment of the patients, who 
have a mild, benign course of the disease with highly potent 
biologics, such as TNF- antagonists is not a good therapeutic 
choice, because of the risk of adverse effects. 
 Beside the side effects of anti-TNF- agents, additional prob-
lems have been raised: among the primary responders only a third 
of patients will maintain remission after 1 year [196], and the ther-
apy is often limited by a loss of efficacy. Therefore, finding novel 
targets and the development of novel therapeutic strategies became 
an urgent need. 
 The strategy to find new targets is based on the main pathologi-
cal alterations that characterize IBD. Since the disease is caused by 
a combination of factors, including genetic susceptibility, immune 
dysregulation, barrier dysfunction, and the change in microbial 
flora, the new therapeutics aim to correct or restore 1./ the genetic 
alterations, 2./ the immune dysregulation, 3./ the barrier dysfunction 
and mucosal resistance 4./ the altered composition of gut flora  
(Fig. 1). 
3.1. Correction of Genetic Alterations 
 Under normal, healthy condition the intestinal mucus layer 
prevents exposure of IECs to luminal bacteria. Several mechanisms 
are involved in protection of intestinal epithelium against luminal 
microbiota, e.g. defensins (secreted by Paneth cells) and the pro-
duction of immunoglobulin A (IgA). PRRs are involved in the pro-
duction of cytokines necessary for the development of immunity 
and have crucial role in innate microbial sensing by IECs, DCs and 
macrophages [30]. Their activation initiates NF-B and MAPK 
signaling pathways resulting in the production of pro-inflammatory 
cytokines and antimicrobial peptides [5, 197]. In addition, auto-
phagy has a crucial role in the maintenance of intracellular homeo-
stasis preventing abnormal accumulation of protein aggregates, 
intracellular components, such as organelles, apoptotic bodies, and 
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microbes [198]. One of the key proteins involved in the execution 
of the autophagic process is ATG16L1 [199]. 
 Though a large number of genetic loci have been found to be 
associated with CD, the polymorphism of two genes, NOD2/ 
CARD15 [200] and ATG16L1 seem to have particular importance 
in the development of the disease [201]. While in healthy subjects 
ATG16L1 encodes threonine at amino acid position 300 
(ATG16L1*300T), ATG16L1 encoding alanine (ATG16L1*300A) 
instead of threonine at the same position increases the risk of the 
development of CD, due to impairement in bacterial capture by 
autophagy [202]. 
 Moreover, patients with CD showed decreased expression of 
mucosal TLR3 and increased expression of TLR4, which results in 
downstream release of inflammatory modulators, for example TNF-
 and IL-1 [203]. Consequently, stimulation of the TLR3 or NOD2 
pathway may represent a new approach of the therapy of IBD. Ex-
perimental data suggest that activation of TLR3 (e.g. by synthetic 
viral RNA) or NOD2 were effective for prevention of DSS-induced 
acute colitis in the mouse [204-206], which implies that stimulation 
of TLR3 or NOD2 signaling may represent a new, successful thera-
peutic strategy for the treatment of CD in those patients who show 
reduced expression of TLR3 or carry NOD2 mutations [207]. On 
the other hand, blocking TLR signaling may represent another ap-
proach for IBD treatment, because TLR2 and TLR4 are up-
regulated in IBD [208]. Experimental data suggest that TLR4 
blockade decreased inflammation in DSS-induced colitis in mice, 
but also interfered with colonic mucosal healing, since anti-TLR4 
antibody treatment during recovery from DSS colitis resulted in 
defective mucosal healing (as described above) [209]. 
 Attempts have been made to develop new TLR4 signaling in-
hibitors. Recently, arylidene malonate derivatives were found to 
suppress LPS-induced production of NF-B, TNF-, IL-1 and 
nitric oxide [210], suggesting its potential therapeutic value for 
various inflammatory diseases. However, their real role in IBD 
remains to be clarified. 
3.2. Restoration of Immune Dysregulation 
 Today it is widely accepted that abnormal immune regulation is 
a key factor in the pathomechanism of IBD and alterations in both 
innate and adaptive immunity have been observed. Dysregulation of 
mucosal immunity in IBD leads to an overproduction of inflamma-
tory cytokines and trafficking of effector leukocytes into the intesti-
nal mucosa, thus resulting in an uncontrolled intestinal inflamma-
tion. Under homeostatic condition there is a balance between regu-
latory (Treg) and effector T-cells (Th1, Th2 and Th17). Mucosal 
inflammation is induced either by an increase in the effector T-cell 
population and an increased production of pro-inflammatory cyto-
kines (such as TNF-, IFN-, IL-1, IL-6, IL-12, IL-17, IL-23) or a 
reduced function of Treg cells and decreased level of anti-
inflammatory cytokines (e.g. TGF-, IL-4, IL-10 or IL-11) pro-
duced by different immune cells located in the lamina propria of the 
intestinal mucosa. Cytokines may therefore be targets for IBD ther-
apy [211]. Moreover, elimination of intestinal inflammation may be 
achieved either by reduction of effector T-cell populations or by 
increasing regulatory T-cell activity [5, 212]. 
 Several reviews have been published recently on the potential 
therapeutic agents in IBD that target the immune dysregulation [7, 
12, 188, 190, 211, 213-218]. 
 Restoration of the immune dysregulation may be achieved by 
several mechanisms, such as inhibition of 1./ pro-inflammatory 
cytokines, 2./ Th1 polarisation and proliferation, 3./ T-cell stimula-
tion (anti-CD3 therapy), 4./ cell adhesion, as well as 5./ by immune 
stimulation (Granulocyte Macrophage Colony Stimulating Factor) 
/GM-CSF)/ and Granulocyte Colony Stimulating Factor /G-CSF/ 
and 6./ by increase of anti-inflammatory cytokines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Therapeutic approaches in IBD targeting different factors (genetic variations, immune dysregulation, barrier dysfunction and intestinal microbiota 
alterations), that are involved in the pathomechanism of IBD according to the recent consensus. 
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3.2.1. Inhibition of Pro-inflammatory Cytokines 
3.2.1.1. Inhibitors of TNF- 
 TNF- is a fundamental mediator of this abnormal immune 
response. TNF- has two forms, a transmembrane and soluble form, 
and its action is mediated by 2 receptors, TNF-R1 (TNF receptor 
type 1, CD120a or p55/60) and TNF-R2 (TNF receptor type 2, 
CD120b or p75/80) [219] resulting in complex and differential 
actions. While the pro-inflammatory effects of TNF- are mediated 
by TNF-R1, the immunoregulatory functions are independent from 
this receptor. Consequently, selective inhibitors of TNF-R1 that 
reduce the pro-inflammatory function of TNF- without affecting 
its immunoregulatory effects, may represent a new therapeutic ap-
proach of IBD. 
 In the last 15 years, biological agents targeting TNF- have 
significantly improved the therapy of IBD refractory to conven-
tional drugs. The efficacy of this therapy alone reflects the plei-
otropic effects of TNF-. 
 Infliximab, a monoclonal chimeric antibody, targeting human 
TNF-, became the first monoclonal antibody available for the 
treatment of CD and UC. The potency of this agent in moderate-to-
severe CD and UC has been one of the most important advances in 
the treatment of IBD. 
 Infliximab also induces T-cell apoptosis, that contributes to its 
therapeutic effect [220]. Namely, in the gut, there is a tight control 
of activation and expansion of T-cells. T-cell expansion is limited 
by apoptosis, and T-cell resistance to apoptosis with consequent T-
cell expansion was observed in patients with IBD, which may con-
tribute to the pathomechanism [221]. Hence, it may be raised that 
induction of apoptosis in T-cells and other effector cells may have 
therapeutic importance in the treatment of IBD and pro-apoptotic 
signaling might be a target for drug development [5]. 
 It has been shown that some anti-TNF- agents induce apopto-
sis in monocytes and lymphocytes both in vitro and in vivo [222, 
223]. Consequently, apoptosis-induction seems to be an important 
part of the therapeutic action of TNF- antagonists and differences 
in their apoptotic efficacy might contribute to the differences found 
in their clinical efficacy. In addition to infliximab, several other 
therapeutic agents that are effective in the treatment of IBD, includ-
ing corticosteroids, sulfasalazine, azathioprine, 6-mercaptopurine 
and anti-IL-12 antibody, induce apoptosis of activated T-cells [222, 
224-226]. 
 Adalimumab, a fully human IgG1 monoclonal antibody to TNF-
, was found to be effective in patients with CD refractory to 
conventional therapy and in patients with an attenuated response to 
infliximab [211, 227, 228]. Recent study showed that adalimumab 
could induce and maintain clinical remission in patients with mod-
erate-to-severe UC as well, who did not have a satisfactory re-
sponse to steroids or immunosuppressive agents [229]. 
 Certolizumab and certolizumab pegol (its PEGylated Fab' 
fragment with increased plasma half-life) are humanized TNF- 
monoclonal antibodies. Majority of the human studies demonstrated 
their effectiveness in maintenance of response and remission in CD 
[230, 231]. However, Sandborn et al. failed to confirm the effec-
tiveness of certoluzimab after 6 weeks treatment [232]. 
 Etanercept is a genetically engineered fusion protein consisting 
of two recombinant human TNF p75 receptors linked to an Fc por-
tion of human IgG1 fragment. It was found to be ineffective for the 
treatment of patients with moderate to severe CD in the same dose 
range that was effective in rheumatoid arthritis [233]. 
 CDP571, an immunoglobulin G4 humanized monoclonal anti-
TNF- antibody showed a slight and short lived reduction in clini-
cal activity of UC [234]. It proved to be less effective than inflixi-
mab and further clinical development of CDP571 for the treatment 
of CD has been discontinued (see review [194]). 
 Novel TNF- inhibitors have been developed, such as golimu-
mab, dersalazine, HMPL-004 and ozoralizumab (ATN-103). These 
compounds are in various phases of the clinical trial process, and 
their real therapeutic values have to be determined [12]. In addition, 
recently a vaccine against TNF- has been developed (TNF- ki-
noid, Debio-01512), as a new mechanism for inhibition of TNF- 
[196], and phase I/II clinical trials in patients with moderate to se-
vere CD were found to be promising [235, 236]. 
3.2.1.2. Inhibition of IL-6 
 IL-6 has a fundamental role in immune regulation and inflam-
mation. The IL-6 receptor (IL-6R) system has both a membrane-
bound (IL-6R) and a soluble form (sIL-6R). Increased serum con-
centrations of IL-6 and sIL-6R have been shown to correlate to 
clinical activity of CD, and animal models have strongly suggested 
the therapeutic potential of anti-IL-6R monoclonal antibody. For 
example, anti-IL-6R monoclonal antibody reduced the symptoms of 
colitis in Th1 cell-mediated murine colitis model. Similarly, block-
ade of sIL-6R in vivo by a newly designed gp130-Fc fusion protein 
resulted in reduction of colitis activity and induction of apoptosis, 
indicating that sIL-6R suppresses mucosal T-cell apoptosis. Ac-
cordingly, it was shown recently that IL-6 induces the anti-
apoptotic genes BCL2 and BCL-XL [237]. These results suggest 
the therapeutic potential of anti-IL-6R monoclonal antibody in CD 
[237, 238]. 
 Tocilizumab (also known as MRA) is a humanized IL-6 recep-
tor antibody, recognizes both the membrane-bound and the soluble 
form of IL-6R and specifically blocks IL-6-induced actions [239]. 
Tocilizumab is expected to ameliorate the autoimmune inflamma-
tory diseases characterized by IL-6 overproduction and has been 
developed as a therapeutic agent for rheumatoid arthritis (see re-
view [240]). Tocilizumab treatment of patients with active CD in-
duced reduction of the disease activity index compared to the pla-
cebo group, however, remission of the disease was registered only 
at very low proportion of the patients [241]. The beneficial effect of 
tocilizumab was confirmed by Nishimoto [242]. 
3.2.1.3. Inhibition of IL-13 
 IL-13 has been shown to be pathogenic in IBD, particularly in 
UC. It impairs the function of the epithelial barrier and also causes 
apoptosis of epithelial cells [10, 11, 243, 244]. IL-13 overexpres-
sion in the inflamed mucosa is particularly characteristic for UC 
and IL-13 is considered as the major effector cytokine in UC [245]. 
 The anti-IL-13 antibody anrukinzumab (IMA-638) as well as 
tralokinumab (CAT-354), a fully human anti-IL-13 antibody are 
under clinical studies (phase IIa) in patients with mild to moderate 
UC. QAX576, another fully human antibody against IL-13, is in 
phase I/II trials in patients with CD, the final results are pending 
[246, 247]. 
3.2.1.4. Inhibition of Mitogen Activated Protein Kinases (MAPKs) 
 Expression of pro-inflammatory cytokines, which are critical in 
the pathogenesis of IBD, is regulated by one or more MAPK path-
ways. Accordingly, activation of several MAPK members was 
found in biopsies from the inflamed mucosa of CD patients [248]. 
 CNI-1493 (semapimod), inhibitor of JNK/p38MAP kinases, 
showed significant clinical improvement of severe CD, confirming 
the potential role of inflammatory MAPKs in the pathogenesis of 
CD [249]. In contrast, a highly potent inhibitor of p38 MAPK, 
BIRB 796 (doramapimod) was studied in chronic active CD in a 
multicenter, multinational trial with placebo control, and the results 
failed to show evidence for clinical efficacy [250]. 
 Concerns with the use of MAPK inhibitors have been raised, 
for example inhibition of p38 and 42/44 MAPK reduces normal 
bactericidal activity of neutrophils [251]. Moreover, ubiquitous 
presence of the MAPK pathways and their involvement in several 
processes suggests that MAPK inhibition should be selective for an 
isoform, rather than general. 
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3.2.1.5. New Avenues Against Pro-inflammatory Cytokines or 
Downstream Signaling Pathways 
 Currently, several novel agents have been developed to target 
either pro-inflammatory cytokines or downstream signaling path-
ways. Pro-inflammatory cytokines IL-17, IL-18 and IL-21 were 
found to be elevated in the inflamed intestinal mucosa of patients 
with IBD [252-254]. Monoclonal antibodies developed against 
these cytokines are currently in phase I/II clinical trials in patients 
with CD. Unexpectedly, secukinumab (AIN 457) targeting IL-17 in 
double-blind, placebo controlled study in patients with CD wors-
ened the disease compared with placebo [255]. In contrast, inhibitor 
of the release of IL-17, vidofludimus (4SC-101/SC12267) showed 
beneficial effect in a single-arm, open-label study, indicating that it 
may be useful in maintaining clinical remission both in patients 
with CD and UC [256]. Further investigation is needed to clarify 
the modulatory role of IL-17 in IBD.  
 On the other hand, gut inflammation can also be restricted by 
blocking the downstream signaling pathways mediated by cytoki-
nes. Signaling molecules that interact with cytokine receptors are 
the Janus kinases (JAK), JAK1, JAK2 and JAK3, which play a 
fundamental role in the development and differentiation of immune 
cells. 
 Tofacitinib, inhibitor of JAK3 was developed recently [257], 
but various clinical efficacies have been experienced. A multicen-
tre, double-blind, placebo controlled study with tofacitinib in pa-
tients with moderate to severe active CD showed no clinically sig-
nificant response following 4 weeks of treatment compared with 
placebo, but in patients with moderate to severe UC it showed im-
provement in both clinical response and remission rates [258, 259]. 
3.2.2. Inhibition of TH1 Polarisation and Proliferation 
3.2.2.1. Inhibition of IL-2 
 Inhibition of the binding of IL-2 to the IL-2 receptor results in 
inhibition of the growth, proliferation and differentiation of T-cells 
to 'effector' T-cells. 
 Basiliximab (chimeric monoclonal antibody) and daclizumab 
(humanized monoclonal antibody) are targeted against the -chain 
of the IL-2 receptor (CD25), and inhibit the binding of IL-2 to the 
IL-2 receptor. However, daclizumab failed to induce a significant 
action in UC [260]. Neither basiliximab increased the effect of cor-
ticosteroids in the induction of remission in patients with corticos-
teroid-resistant moderate to severe UC [261]. 
3.2.2.2. Inhibition of IL-12 and IL-23 
 CD is associated with an enhanced Th1 cytokine response, 
which results in increased production of IL-12, a pro-inflammatory 
cytokine, that stimulates the production of IFN- and TNF-. IL-12 
is also involved in the differentiation of naïve T-cells into Th1 cells. 
It is a heterodimeric protein with 2 subunits: the p35 and p40. The 
structurally similar cytokine IL-23 (its p40 subunit is identical to 
IL-12p40, and its p19 subunit shows certain similarities to IL-12 
p35) has also an important role in intestinal inflammation, in con-
junction with IL-6 and TGF-1. IL-23 stimulates naïve CD4+ T 
cells to differentiate to Th17 cells. The highly aggressive immune 
response together with IL-12/IL-23 could have a determining role 
in initiation and perpetuation of chronic intestinal inflammation in 
CD [262, 263]. 
 Recently p40 peptide-based vaccines have been developed. 
Pretreatment of rats with the vaccines induced specific antibodies to 
IL-12 and IL-23, which was associated with improvement of intes-
tinal inflammation and fibrosis, indicating that the vaccine may 
provide a potential approach for the long-term treatment of CD 
[264]. 
 A human study showed that treatment with a human mono-
clonal antibody against IL-12 may induce clinical responses and 
remissions in patients with active CD. This treatment is associated 
with decreased Th1-mediated inflammatory cytokines at the site of 
disease [265]. 
 Ustekinumab, and briakinumab are human monoclonal antibod-
ies against IL-12 and IL-23, both targeting the p40 subunit. Usteki-
numab significantly increased the rates of response and remission 
as maintenance therapy, and it may be particularly useful in patients 
who previously did not respond to anti-TNF therapy [266]. Briaki-
numab, however, in patients with moderate to severe CD was not 
effective for the induction or maintenance of remission ([267]. 
 Apilimod is an inhibitor of the transcription of IL-12 and IL-23. 
In a randomised controlled trial apilimod failed to induce signifi-
cantly greater effect than placebo treatment [268]. 
3.2.2.3. Interferon- 
 IFN- was found to be elevated in all genetic animal models of 
IBD and seems to have determining role in the development of Th1 
responses. If the target of IBD therapy is to reduce Th1 responses, 
then inhibition of IFN- represents one potential therapeutic ap-
proach. 
 Fontolizumab, a humanized monoclonal antibody to IFN- was 
shown to have a beneficial effect on disease activity [12, 211, 269]. 
An other study suggested that though a strong clinical response was 
not induced by fontolizumab, a significant decrease in C-reactive 
protein levels was observed. Further studies are necessary to deter-
mine its efficacy [270]. 
3.2.3. Inhibition of T-cell Stimulation 
 Since intestinal inflammation may be resulted by an increased 
activity of the effector T-cell population with excessive inflamma-
tory responses and CD3 is required for T-cell activation, drugs that 
target T-cell activation may exert therapeutic effect in IBD. 
 Visilizumab, a humanized anti-CD3 monoclonal antibody was 
demonstrated to induce apoptosis in activated T-cells selectively, 
and enhance the production of IL-10, a potent anti-inflammatory 
cytokine [271]. It proved to be effective against T-cell transfer coli-
tis [272]. The results of an open-label phase I human study with 
visilizumab in patients with severe corticosteroid-refractory UC 
suggested that it may be clinically beneficial [273]. 
 Another study confirmed this beneficial effect of visilizumab in 
a pilot randomized phase I/II study. Visilizumab improved both 
symptomatic and clinical responses in severe, steroid-refractory 
UC, though, all patients experienced adverse reactions [274]. How-
ever, in a randomised, double-blind, placebo-controlled study vis-
ilizumab was not effective for severe, corticosteroid-refractory UC 
[275]. The same conclusion was drawn by Wood [276]. 
 CD40 is also involved in T-cell activation. Humanized mono-
clonal antibody against CD40L has been developed, however in a 
phase II trial for CD due to side effect (thromboembolism) the trial 
was halted [277]. 
3.2.4. Inhibition of Cell Adhesion 
 Lymphocyte trafficking to the gut is a basically important step 
in the initiation and maintenance of intestinal inflammation in pa-
tients with IBD. Alpha 4 integrin, a cell-surface glycoprotein in-
volved in the adhesion, migration and activation of immune cells, is 
expressed on most of the lymphocytes, and combined with either a 
1 subunit (that interacts predominantly with the endothelial 
ligands, vascular cellular adhesion molecule 1 /VCAM-1/) or a 7 
subunit (that interacts predominantly with the mucosal addressin 
cellular adhesion molecule 1 (Mad-CAM-1)) [278]. The interaction 
between 47 integrin and Mad-CAM-1 is important in mediating 
leukocyte homing to gut mucosa [279]. Several therapeutic agents 
have been developed that specifically target the 47 subunit of 
integrin. 
 Natalizumab, a humanized monoclonal antibody against the cell 
adhesion molecule 4-integrin subunit, was proved to be effective 
in experimental colitis both in the mouse and the rat [280, 281]. 
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Moreover, the effect of natalizumab has been studied also in hu-
mans, and it was shown to block the adhesion and migration of 
white blood cells into the gut and to reduce chronic inflammation 
associated with CD [282]. Reviews based on relevant literature and 
meta-analysis of the controlled trials of natalizumab suggested that 
the therapy was superior to placebo in inducing remission of CD 
[283, 284]. However, natalizumab therapy is associated with an 
increased risk of reactivation of latent John Cunningham (JC) virus, 
which causes the potentially fatal progressive multifocal leukoen-
cephalopathy (PML). The risk to develop PML is increased by the 
presence of anti-JC virus antibodies, and previous or concomitant 
treatment with immunosuppressive (IF-1 or azathioprine) agents 
[285]. 
 Vedolizumab (MNL-0002) is gut-specific, 47-integrin-
neutralizing monoclonal antibody, that appears to lack systemic 
effects. It was particularly effective in UC and also in CD, indicat-
ing that vedolizumab might be therapeutic option for the treatment 
of therapy-refractory patients [286]. A recent review evaluated the 
safety and efficacy of vedolizumab for the treatment of CD, and it 
was concluded that vedolizumab is an effective and well-tolerated 
drug [287]. Though it does not increase the risk of infection, it was 
demonstrated that vedolizumab may reduce the number of Treg 
cells and consequently their suppressive effect on colonic inflam-
mation (see review [288]). 
 Alicaforsen (ISIS 2302) is an antisense oligodeoxynucleotide to 
ICAM-1 [289]. Experimentally, it inhibited the DSS-induced colitis 
both in mice and rats [289, 290], but in human studies both im-
provement of clinical symptoms and lack of effect have been shown 
in CD (see reviews [12, 211, 291, 292]). In patients with active UC 
alicaforsen enemas induced a beneficial effect, and the drug was 
well tolerated [291]. 
3.2.5. Immune Stimulation 
 Though granulocyte macrophage colony stimulating factor 
(GM-CSF) and granulocyte colony stimulating factor (G-CSF) are 
hematopoietic growth factors, they stimulate cells of the innate 
immune system (neutrophils, macrophages and DCs). They have 
also been shown to be produced within Paneth cells of intestinal 
mucosa, and their receptors are expressed within IECs [293]. 
Moreover, GM-CSF has been demonstrated to promote prolifera-
tion within these cells [294]. 
 GM-CSF has been shown to reduce DSS-induced colitis and 
decrease the levels of pro-inflammatory cytokines (TNF- and IL-
1) in colonic tissue samples [295, 296]. These results were con-
firmed recently; GM-CSF decreased the DSS-induced colitis and 
the expression of pro-inflammatory cytokines. In addition, the dura-
tion of ulcer healing was shorter and epithelial regeneration was 
facilitated in GM-CSF-treated mice [295]. Based on these preclini-
cal results, a potential role for GM-CSF in the therapy of patients 
with IBD has been raised. 
 Sargramostim (recombinant human GM-CSF) and filgrastim 
(recombinant human G- CSF) have been examined in several hu-
man studies and majority of them suggested a significant improve-
ment and remission of CD ([297] and reviews [12, 298]). However, 
sargramostim in a phase III multicentre double-blind, placebo con-
trolled study in patients with active CD failed to induce a signifi-
cant difference in clinical efficacy compared to placebo. Further 
human studies are necessary to reveal their role in the treatment of 
IBD [211]. 
3.2.6. Anti-inflammatory Cytokines 
3.2.6.1. IL-10 
 IL-10 reduces the production of pro-inflammatory cytokines IL-
1, IL-6 and TNF-, downregulates and controls the acute inflam-
mation and thereby may improve the course of IBD. IL-10 poly-
morphisms have been shown to be associated with IBD and muta-
tions in IL-10 and IL-10 receptor (IL-10R) in patients with very 
early onset IBD was observed [299]. 
 However, Buruiana et al. [300] on the basis of a systematic 
review of the literature concluded that IL-10 does not appear to 
provide any benefit for the treatment of active CD. 
3.2.6.2. IL-11 
 IL-11 besides its thrombocytopoietic properties improves the 
mucosal barrier function and inhibits the inflammatory reaction by 
reducing expression of NF-B and in turn IL-1, TNF- and other 
proinflammatory peptides [301]. Therefore IL-11 was examined on 
experimental colitis in the rat induced by trinitrobenzene sulfonic 
acid (TNBS), where IL-11 exerted protective effect [302]. Recent 
findings confirmed the beneficial action of IL-11: administration of 
exogenous IL-11 was found to be protective against lethal colitis in 
TLR2-deficient mice (TLR2 is involved in maintaining epithelial 
barrier function) [303]. However, in a human study recombinant 
human IL-11 was less effective than prednisolone in the treatment 
of CD [304]. 
3.2.6.3. Interferon--1a (IFN--1a) 
 Data of the literature reflect conflicting results on the effect of 
IFN--1a in IBD. Some studies indicate that IFN--1a exerts a 
therapeutic effect, while others found that IFN--1a did not produce 
a significant therapeutic action compared with placebo. Recent 
clinical trial in patients with CD came to the conclusion that there 
was no difference between the effects of the administration of IFN-
-1a and placebo [305, 306]. 
3.3. Restoration of Barrier Dysfunction and Stimulation of Mu-
cosal Healing and Resistance 
 Repeated intestinal epithelial damage and the consequent dis-
ruption of the intestinal barrier function is a key mechanism of IBD 
[3, 6]. Namely, the alteration of intestinal barrier function may re-
sult in translocation of commensal bacteria into the intestinal wall, 
leading to uncontrolled T-cell activation and inflammation. Damage 
of barrier integrity, with increased antigen and bacterial uptake is 
believed to be important in the pathophysiology of CD [4]. 
 An intact barrier function of the intestinal epithelium prevents 
translocation of commensal bacteria into the mucosa. Consequently, 
though mucosal healing has been considered as a sign of complete 
healing of gut inflammation, it should be emphasized that mucosal 
healing can be considered as an initial step in suppression of in-
flammation [307]. In a systematic review Neurath and Travis [307] 
analyzed the influence of conventional therapeutic agents as well as 
the biologics on the healing of intestinal mucosal injury in IBD, and 
they concluded that while corticosteroids have little or no positive 
effects on induction/maintenance of mucosal healing in CD (but 
induced healing in patients with UC), azathioprine, in a lesser ex-
tent methotrexate, as well as natalizumab, infliximab, adalimumab 
and certolizumab pegol could induce mucosal healing [307]. 
 Following injury of intestinal mucosa, IECs migrate into the 
damaged area to restore barrier integrity [298, 308], followed by 
proliferation of IECs to correct the epithelial defect. Finally, differ-
entiation of IECs is necessary to restore mucosal barrier and epithe-
lial function. These consecutive events (restitution, proliferation 
and differentiation) are mediated by regulatory proteins (such as 
chemokines), defensins, as well as by growth factors [298]. Growth 
factors have crucial role in cell restitution/proliferation/ differentia-
tion, and in angiogenesis. Moreover, TGF- inhibits the differentia-
tion of naïve T-cells to Th1/Th2 subtypes. 
3.3.1. Growth Hormone (GH) 
 GH, a regulatory peptide that stimulates aminoacid and electro-
lyte uptake by the intestine, decreases intestinal permeability and 
stimulates collagen synthesis by induction of the expression of insu-
lin-like growth factor (IGF). IGF was shown to promote epithelial 
repair in intestinal inflammation in preclinical animal models. For 
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example, recombinant human growth hormone induced protective 
effects in TNBS-induced colitis [309]. A preliminary study showed 
that human growth factor was effective in CD, it improved the 
clinical symptoms (the number of liquid/soft stools, severity of 
abdominal pain and overall well being) and a statistically signifi-
cant increase in circulating levels of IGF-1 was observed [310]. 
Further, placebo controlled human studies should be performed to 
determine the real place of growth factor in the therapy of IBD. 
3.3.2. Epidermal Growth Factor (EGF) 
 Human recombinant EGF was shown to be effective in experi-
mental colitis induced by TNBS given prophylactically, before the 
induction of colitis [311]. In UC patients EGF enemas administered 
parallel with mesalamine resulted in a significant improvement of 
symptoms [312], however, the effect of EGF enema alone (with 
placebo) has not been studied.  
3.3.3. Keratinocyte Growth Factor (KGF) 
 KGF-1 and -2 are ligands of the fibroblast growth factor (FGF) 
family. KGFs may have role in wound healing and maintaining 
epithelial homeostasis. Expression of KGF-1 was found to be up-
regulated in patients with active CD and UC, indicating that KGF 
may have role in the pathomechanism of IBD [313]. 
 In animal models, KGF-2 proved to be protective against DSS-
induced colitis given both prophylactically and therapeutically, both 
the clinical as well as the histological symptoms were improved 
significantly [314, 315]. However, human recombinant KGF-2 
failed to improve symptoms in patients with moderate to severe 
colitis, when compared with placebo. The contradictory results 
gained from animal experiments and human studies were explained 
by miscalculation in estimating the target dosage in humans [316]. 
However, a recent study confirmed the previous finding; KGF-2 
(and EGF) did not show efficacy in phase II trials concerning pa-
tients with either CD or UC (see review [298]). 
3.3.4. Transforming Growth Factor  (TGF-) 
 The TGF- superfamily in the intestinal epithelium controls cell 
proliferation, differentiation, apoptosis, as well as the activation 
state of differentiated cell types. The TGF- superfamily can further 
be divided into subfamilies and within the gut these include the 
TGF- and bone morphogenetic protein (BMP) subfamilies. TGF- 
superfamily ligands appear to facilitate the maintenance of normal 
epithelial homeostasis. Dysfunction of TGF-/BMP signaling 
within the intestinal epithelium has been raised to be involved in the 
pathogenesis of human colitis [317]. 
 Recent preclinical studies demonstrated the role of BMP-7 both 
as a prophylactic and a therapeutic agent in experimental colitis 
induced by TNBS in the rat. Cytokine analysis of treated rats 
showed a reduced mRNA expression of pro-inflammatory cytoki-
nes, like IL-6, TNF-, and ICAM-1 and decreased expression of 
pro-fibrogenic cytokines (TGF-1) [318]. 
3.3.5. Vascular Endothelial Growth Factor (VEGF) 
 VEGF has basic role in the regulation of angiogenic processes 
during both development and in pathologic conditions (inflamma-
tion or tumorgenesis). Six mammalian VEGF family ligands 
(VEGF-A - VEGA-F) and 3 distinct receptors (VEGFR-1, VEGFR-
2 and VEGFR-3) have been described. In rats, anti-VEGF antibody 
was investigated in colitis induced by iodoacetamide given intra-
colonically, and the results showed markedly less severe colitis as 
well as significant reductions in pro-inflammatory cytokines com-
pared with controls. The beneficial effect of anti-VEGF antibody on 
colitis may be due to its moderating effects on vascular permeabil-
ity and inflammatory cell recruitment [319]. Further studies showed 
that the levels of VEGF-A and VEGFR-2 were increased in patients 
with IBD as well as in DSS-treated mice. Furthermore, overexpres-
sion of VEGF-A in mice worsened DSS-induced colitis, whereas 
administration of a soluble VEGF receptor led to decreased colonic 
inflammation [320]. Another angiogenic factor, placental growth 
factor (PIGF), has also been suggested to be a marker of pathologic 
angiogenesis and may play a critical role in pathogenesis of UC. 
Accordingly, inhibition of pathologic angiogenesis by either anti-
VEGF or anti-PIGF, was demonstrated to be a new approach to 
attenuate UC [321, 322]. 
 The role of additional growth factors, such as glucagon-like 
peptide or trefoil factors have been raised to be involved in healing 
and restoration of mucosal integrity in IBD [298, 323]. Some of 
them have been studied in clinical trials or experimental colitis 
models and their potential role in the treatment of IBD remains to 
be further analyzed. 
 However, it should keep in mind that both UC and CD are as-
sociated with dysplastic lesions and with increased risk of the de-
velopment of colorectal cancer [324]. Since growth factors may 
induce stimulation of dysplastic tissues, growth factor therapy rep-
resents a potential risk for induction of malignant alterations in 
these patients [325]. 
 In contrast, the recent results of Dube et al. [326] suggested that 
EGF receptors by modulating epithelial regeneration and reducing 
inflammation might limit the subsequent tumorgenesis. Namely, 
since chronic inflammation increases the risk of the development of 
cancer in IBD patients, disrupting the cycle of inflammation and 
epithelial injury may result in reduction of cancer risk. The authors 
showed that inactivation of the EGF-receptors accelerated the pro-
gression of colorectal tumors in mouse models of colitis, which 
suggests that therapy with EGF may reduce long-term cancer risk. 
3.4. Normalization of the Altered Composition of Microbial 
Flora 
 Convincing evidence from both animal models and clinical 
observations indicate that the microbiota is the most probable factor 
that initiates chronic inflammation in CD. In accordance with this 
concept, antibiotics are one potential therapy in the treatment of 
active CD and UC. Moreover, it was shown that intestinal bacteria 
are necessary for the development of experimental colitis in the 
mouse [225, 327]. 
 Bacterial adhesion and invasion into the intestinal mucosa may 
be particularly important in the development of intestinal mucosal 
inflammation, e.g., as in the case of Escherichia coli [328]. Though 
several pathogens have been supposed to be involved in the devel-
opment of IBD (see section 2.3.), none of them have been proven to 
have a causal role, rather, microbial antigens that are present in the 
intestinal lumen under normal conditions seem to drive intestinal 
inflammation [213]. 
 The microbiota is involved in both beneficial and deleterious 
processes in the intestinal tract. Epithelial cells may act as a mu-
cosal protective and antimicrobial defensive system. Antimicrobial 
peptides, such as defensins, released by IECs and Paneth cells, play 
an essential role in host defense. Clinical studies showed reduced 
expression of both - and -defensins and the consequent reduced 
killing of certain microorganisms by the intestinal mucosa of pa-
tients with CD [329]. These findings indicate that defensin defi-
ciency should be corrected in patients with CD. The nuclear recep-
tor peroxisome proliferator-activated receptor gamma (PPAR-) 
plays an essential role in intestinal homeostasis. PPAR- was 
shown to function as an antimicrobial factor by maintaining consti-
tutive epithelial expression of a subset of -defensin in the colon. 
Defective killing of several intestinal microbiota in colonic mucosa 
of PPAR- mutant animals, for example Candida albicans, Bacter-
oides fragilis, Enterococcus faecalis and Escherichia coli was dem-
onstrated recently [330]. Furthermore, the PPAR- agonist rosigli-
tazone is a potent inducer of a subset of -defensin in mouse colon. 
Accordingly, rosiglitazone was shown to be efficacious in mild-to-
moderate UC [331]. This finding raises a new potential mechanism 
for the improvement of gut barrier function in CD. 
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 Enteric flora is altered in IBD patients. As intestinal bacteria are 
supposed to be involved in the pathogenesis of the disease, the 
therapeutic value of antibiotics in the treatment of IBD have been 
studied. Metronidazol, ciprofloxacin, rifamixin failed to induce a 
significant effect in UC, and also the results of clinical studies with 
metronidazole, ornidazole, ciprofloxacin, tobramycin, clarithromy-
cin, co-trimoxazole and anti-mycobacterial agents in CD are con-
flicting and not convincing [7, 141, 142]. 
 Since gastrointestinal microbiota has prominent role in driving 
inflammation in IBD, treatments that modulate the intestinal micro-
biota have been intensively analyzed. To counterbalance harmful 
bacteria, manipulation of the bacterial flora with probiotics (non-
pathogenic, beneficial bacteria) and prebiotics (dietary components 
that stimulate the growth of beneficial bacteria) is a potential alter-
native. Several mechanisms have been raised to be responsible for 
the potential beneficial effects of probiotics, such as production of 
bactericidal substances, competition with pathogens and toxins for 
adherence to the intestinal epithelium, enhancement of the innate 
immunity, modulation of pathogen-induced inflammation via TLR-
regulated signaling pathways and stimulation of intestinal epithelial 
cell survival and barrier functions (see review [332]). Results from 
experimental models of colitis suggest that TLR2, TLR4 and TLR9 
are necessary for some probiotics to exert their anti-inflammatory 
effects in vivo [333]. However, in the light of literature probiotics 
show variable evidence for their efficacy [334, 335]. E.g. probiotics 
(Lactobacillus GG) were found to be ineffective in preventing re-
currence after curative resection for CD [336]. Similarly, Mack 
[337] concluded in his review that there is little evidence and not 
enough convincing proof from trials for the effectiveness of probi-
otic in CD as well as in UC, though, clinical practice guidelines 
suggests their potential benefit in selected patients. 
 Anderson et al. [338] recently published a review focusing on 
the efficacy of fecal microbiota transplantation (FMT). FMT was 
administered via colonoscopy/enema or via enteral tube. In patients 
treated for their IBD, the majority experienced a reduction of symp-
toms and disease remission. It was concluded, that though faecal 
microbiota transplantation may be an effective treatment of IBD, 
the evidence for the therapeutic effectiveness is limited and weak. 
Further randomized, controlled clinical studies are required to clar-
ify the potential therapeutic value of FMT. 
 As mentioned above, IBD is common in Western countries, 
where helminths are rare, and uncommon in less developed areas, 
which may be associated with poor sanitation and the concomitant 
helminth infections. Experimental data are in agreement with this 
assumption: it was shown that mice colonized with helminths are 
protected from the development of experimental colitis in various 
animal models (TNBS, DSS, IL-10 KO, T-cell transfer colitis) due 
to the activation of Treg cells and inhibition of effector T-cells 
[180]. Efficacy of helminths in CD and UC has been studied and 
the results suggest that Trichuris suis ova treatment was safe, and 
efficacious and may offer alternative therapeutic possibility for CD. 
Similar beneficial effect was observed in patients with UC (im-
provement: 47.3 % vs. 16.7 % placebo) [339, 340]. Recent experi-
mental results showed a beneficial effect of the local treatment with 
Trichinella spiralis antigens in experimental colitis induced by 
dinitrobenzene sulfonic acid in mice, which suggest that helminth 
antigen-based therapy should be applied for IBD instead of infec-
tion with live parasites [341]. 
4. CONCLUSION 
 The intensive research over the last decade has led to better 
understanding of the pathophysiology of IBDs. IBDs are initiated 
and perpetuated by an impaired immune response against the gut 
microbiota in genetically susceptible individuals. Predisposition to 
disease is determined by genes encoding immune responses which 
are triggered by several environmental influences. According to the 
present concept the disease is caused by a combination of factors, 
including genetics, immune dysregulation, barrier dysfunction, the 
change in microbial flora and environmental stimuli. The novel 
therapeutics, such as monoclonal antibodies, small molecule inhibi-
tors, peptides, and vaccines target specific signaling pathways in-
volved in initiation, perpetuation and maintenance of intestinal 
inflammation. During the course of IBD several molecules were 
shown to be upregulated or downregulated in patients with IBD, 
which raised that they are potentially targets for drug development. 
However, in human studies many of the newly developed mole-
cules failed to show significant biological action and had limited 
clinical efficacy. Moreover, antibody production to the therapeutic 
monoclonal antibodies may result in reduction of the efficacy of the 
biologics. Consequently, need for the development of additional 
strategies and targets is raised. 
 Moreover, it’s also worth considering that combination of dif-
ferent factors may lead to the development of IBD. In addition, also 
the levels of cytokines potentially involved in pathophysiology of 
intestinal inflammation are different at the different stages of the 
disease; e.g. IFN- is significantly higher in early stage compared 
with late stage of IBD [342]. Consequently, more than one thera-
peutic option may be necessary during the course of the disease. 
The “step-up” therapeutic strategy represents partly this concept, 
however, there are limited studies on the therapeutic efficacy of the 
combination of agents with different mechanism of action [12]. 
CONFLICT OF INTEREST 
 The authors confirm that this article content has no conflicts of 
interest. 
ACKNOWLEDGEMENTS 
 Declared none. 
REFERENCES 
[1] Strober W, Fuss I, Mannon P. The fundamental basis of 
inflammatory bowel disease. J Clin Invest 2007; 117: 514-21. 
[2] Xavier RJ, Podolsky DK. Unravelling the pathogenesis of 
inflammatory bowel disease. Nature 2007; 448: 427-34. 
[3] Henderson P, van Limbergen JE, Schwarze J, Wilson DC. Function 
of the intestinal epithelium and its dysregulation in inflammatory 
bowel disease. Inflamm Bowel Dis 2011; 17: 382-95. 
[4] Keita AV, Soderholm JD. Barrier dysfunction and bacterial uptake 
in the follicle-associated epithelium of ileal Crohn's disease. Ann N 
Y Acad Sci 2012; 1258: 125-34. 
[5] Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of 
IBD pathogenesis: implications for future therapies. Inflamm 
Bowel Dis 2006; 12: 1068-83. 
[6] Salim SY, Soderholm JD. Importance of disrupted intestinal barrier 
in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 
362-81. 
[7] Triantafillidis JK, Merikas E, Georgopoulos F. Current and 
emerging drugs for the treatment of inflammatory bowel disease. 
Drug Des Devel Ther 2011; 5: 185-210. 
[8] Engel MA, Becker C, Reeh PW, Neurath MF. Role of sensory 
neurons in colitis: increasing evidence for a neuroimmune link in 
the gut. Inflamm Bowel Dis 2011; 4: 1030-3. 
[9] MacDonald TT, Monteleone I, Fantini MC, Monteleone G. 
Regulation of homeostasis and inflammation in the intestine. 
Gastroenterology 2011; 6: 1768-75. 
[10] Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted 
NK T cells that produce IL-13 characterize an atypical Th2 
response in ulcerative colitis. J Clin Invest 2004; 10: 1490-7. 
[11] Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F. 
Immunoregulation in the gut: success and failures in human 
disease. Gut 2002; 50 (Suppl 3): 60-4. 
[12] Danese S. New therapies for inflammatory bowel disease: from the 
bench to the bedside. Gut 2012; 61: 918-32. 
[13] Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory 
bowel diseases: good, bad or ugly? World J Gastroenterol 2007; 
13: 6134-9. 
12    Current Pharmaceutical Design, 2014, Vol. 20, No. 00 Gyires et al. 
[14] Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical 
aspects and established and evolving therapies. Lancet 2007; 369: 
1641-57. 
[15] Baumgart DC. The diagnosis and treatment of Crohn's disease and 
ulcerative colitis. Dtsch Arztebl Int 2009; 106: 123-33. 
[16] Hanauer SB, Sandborn W. Management of Crohn's disease in 
adults. Am J Gastroenterol 2001; 96: 635-43. 
[17] Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and patho-
physiology of inflammatory bowel disease. Clin Microbiol Rev 
2002; 15: 79-94. 
[18] Biancone L, Michetti P, Travis S, et al. European evidence-based 
Consensus on the management of ulcerative colitis: Special 
situations. J Crohns Colitis 2008; 2: 63-92. 
[19] Itzkowitz SH, Present DH. Consensus conference: Colorectal 
cancer screening and surveillance in inflammatory bowel disease. 
Inflamm Bowel Dis 2005; 11: 314-21. 
[20] Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. 
Ulcerative colitis and Crohn's disease: a comparison of the 
colorectal cancer risk in extensive colitis. Gut 1994; 35: 1590-2. 
[21] Lakatos PL. Recent trends in the epidemiology of inflammatory 
bowel diseases: up or down? World J Gastroenterol 2006; 12: 
6102-8. 
[22] Cannom RR, Kaiser AM, Ault GT, Beart RW, Jr., Etzioni DA. 
Inflammatory bowel disease in the United States from 1998 to 
2005: has infliximab affected surgical rates? Am Surg 2009; 75: 
976-80. 
[23] Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. 
Concordance of inflammatory bowel disease among Danish twins. 
Results of a nationwide study. Scand J Gastroenterol 2000; 35: 
1075-81. 
[24] Sherlock P, Bell BM, Steinberg H, Almy TP. Familial occurrence 
of regional enteritis and ulcerative colitis. Gastroenterology 1963; 
45: 413-20. 
[25] Spehlmann ME, Begun AZ, Burghardt J, Lepage P, Raedler A, 
Schreiber S. Epidemiology of inflammatory bowel disease in a 
German twin cohort: results of a nationwide study. Inflamm Bowel 
Dis 2008; 14: 968-76. 
[26] Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. Genetics 
versus environment in inflammatory bowel disease: results of a 
British twin study. BMJ 1996; 312: 95-6. 
[27] Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative 
colitis and Crohn's disease in an unselected population of 
monozygotic and dizygotic twins. A study of heritability and the 
influence of smoking. Gut 1988; 29: 990-6. 
[28] Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-
analysis increases to 71 the number of confirmed Crohn's disease 
susceptibility loci. Nat Genet 2010; 42: 1118-25. 
[29] Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions 
have shaped the genetic architecture of inflammatory bowel 
disease. Nature 2012; 491: 119-24. 
[30] Franchi L, Warner N, Viani K, Nunez G. Function of Nod-like 
receptors in microbial recognition and host defense. Immunol Rev 
2009; 227: 106-28. 
[31] Kersse K, Bertrand MJ, Lamkanfi M, Vandenabeele P. NOD-like 
receptors and the innate immune system: coping with danger, 
damage and death. Cytokine Growth Factor Rev 2011; 22: 257-76. 
[32] Manicassamy S, Pulendran B. Modulation of adaptive immunity 
with Toll-like receptors. Semin Immunol 2009; 21: 185-93. 
[33] Bonen DK, Ogura Y, Nicolae DL, et al. Crohn's disease-associated 
NOD2 variants share a signaling defect in response to 
lipopolysaccharide and peptidoglycan. Gastroenterology 2003; 124: 
140-6. 
[34] Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 
leucine-rich repeat variants with susceptibility to Crohn's disease. 
Nature 2001; 411: 599-603. 
[35] Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in 
NOD2 associated with susceptibility to Crohn's disease. Nature 
2001; 411: 603-6. 
[36] Ogura Y, Saab L, Chen FF, Benito A, Inohara N, Nunez G. Genetic 
variation and activity of mouse Nod2, a susceptibility gene for 
Crohn's disease. Genomics 2003; 81: 369-77. 
[37] Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 
variants in Japanese patients with Crohn's disease. 
Gastroenterology 2002; 123: 86-91. 
[38] McGovern DP, Hysi P, Ahmad T, et al. Association between a 
complex insertion/deletion polymorphism in NOD1 (CARD4) and 
susceptibility to inflammatory bowel disease. Hum Mol Genet 
2005; 14: 1245-50. 
[39] Franke A, Ruether A, Wedemeyer N, Karlsen TH, Nebel A, 
Schreiber S. No association between the functional CARD4 
insertion/deletion polymorphism and inflammatory bowel diseases 
in the German population. Gut 2006; 55: 1679-80. 
[40] Van Limbergen J, Russell RK, Nimmo ER, et al. Contribution of 
the NOD1/CARD4 insertion/deletion polymorphism +32656 to 
inflammatory bowel disease in Northern Europe. Inflamm Bowel 
Dis 2007; 13: 882-9. 
[41] Pierik M, Joossens S, Van Steen K, et al. Toll-like receptor-1, -2, 
and -6 polymorphisms influence disease extension in inflammatory 
bowel diseases. Inflamm Bowel Dis 2006; 12: 1-8. 
[42] Franchimont D, Vermeire S, El Housni H, et al. Deficient host-
bacteria interactions in inflammatory bowel disease? The toll-like 
receptor (TLR)-4 Asp299gly polymorphism is associated with 
Crohn's disease and ulcerative colitis. Gut 2004; 53: 987-92. 
[43] Brand S, Staudinger T, Schnitzler F, et al. The role of Toll-like 
receptor 4 Asp299Gly and Thr399Ile polymorphisms and 
CARD15/NOD2 mutations in the susceptibility and phenotype of 
Crohn's disease. Inflamm Bowel Dis 2005; 11: 645-52. 
[44] Torok HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. 
Polymorphisms of the lipopolysaccharide-signaling complex in 
inflammatory bowel disease: association of a mutation in the Toll-
like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 
112: 85-91. 
[45] Gazouli M, Mantzaris G, Kotsinas A, et al. Association between 
polymorphisms in the Toll-like receptor 4, CD14, and 
CARD15/NOD2 and inflammatory bowel disease in the Greek 
population. World J Gastroenterol 2005; 11: 681-5. 
[46] Hume GE, Fowler EV, Doecke J, et al. Novel NOD2 haplotype 
strengthens the association between TLR4 Asp299gly and Crohn's 
disease in an Australian population. Inflamm Bowel Dis 2008; 14: 
585-90. 
[47] Rigoli L, Romano C, Caruso RA, et al. Clinical significance of 
NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide 
polymorphisms in inflammatory bowel disease. World J 
Gastroenterol 2008; 14: 4454-61. 
[48] Lakatos PL, Lakatos L, Szalay F, et al. Toll-like receptor 4 and 
NOD2/CARD15 mutations in Hungarian patients with Crohn's 
disease: phenotype-genotype correlations. World J Gastroenterol 
2005; 11: 1489-95. 
[49] Browning BL, Huebner C, Petermann I, et al. Has toll-like receptor 
4 been prematurely dismissed as an inflammatory bowel disease 
gene? Association study combined with meta-analysis shows 
strong evidence for association. Am J Gastroenterol 2007; 102: 
2504-12. 
[50] Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen 
GW. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease 
in a New Zealand Caucasian cohort. J Gastroenterol Hepatol 2007; 
22: 1760-6. 
[51] Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-
analysis increases to 71 the number of confirmed Crohn's disease 
susceptibility loci. Nat Genet 2010; 42: 1118-25. 
[52] Zhernakova A, Festen EM, Franke L, et al. Genetic analysis of 
innate immunity in Crohn's disease and ulcerative colitis identifies 
two susceptibility loci harboring CARD9 and IL18RAP. Am J 
Hum Genet 2008; 82: 1202-10. 
[53] Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association 
scan of nonsynonymous SNPs identifies a susceptibility variant for 
Crohn disease in ATG16L1. Nat Genet 2007; 39: 207-11. 
[54] Lakatos PL, Szamosi T, Szilvasi A, et al. ATG16L1 and IL23 
receptor (IL23R) genes are associated with disease susceptibility in 
Hungarian CD patients. Dig Liver Dis 2008; 40: 867-73. 
[55] Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the 
autophagy gene IRGM and multiple other replicating loci 
contribute to Crohn's disease susceptibility. Nat Genet 2007; 39: 
830-2. 
[56] Prescott NJ, Fisher SA, Franke A, et al. A nonsynonymous SNP in 
ATG16L1 predisposes to ileal Crohn's disease and is independent 
of CARD15 and IBD5. Gastroenterology 2007; 132: 1665-71. 
[57] Kaser A, Lee AH, Franke A, et al. XBP1 links ER stress to 
intestinal inflammation and confers genetic risk for human 
inflammatory bowel disease. Cell 2008; 134: 743-56. 
Gut Inflammation: Current Update on Pathophysiology Current Pharmaceutical Design, 2014, Vol. 20, No. 00    13 
[58] McGovern DP, Gardet A, Torkvist L, et al. Genome-wide 
association identifies multiple ulcerative colitis susceptibility loci. 
Nat Genet 2010; 42: 332-7. 
[59] Libioulle C, Louis E, Hansoul S, et al. Novel Crohn disease locus 
identified by genome-wide association maps to a gene desert on 
5p13.1 and modulates expression of PTGER4. PLoS Genet 2007; 
3: e58. 
[60] Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association 
study identifies IL23R as an inflammatory bowel disease gene. 
Science 2006; 314: 1461-3. 
[61] Glas J, Seiderer J, Wetzke M, et al. rs1004819 is the main disease-
associated IL23R variant in German Crohn's disease patients: 
combined analysis of IL23R, CARD15, and OCTN1/2 variants. 
PLoS One 2007; 2: e819. 
[62] Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association 
defines more than 30 distinct susceptibility loci for Crohn's disease. 
Nat Genet 2008; 40: 955-62. 
[63] Hisamatsu T, Kanai T, Mikami Y, Yoneno K, Matsuoka K, Hibi T. 
Immune aspects of the pathogenesis of inflammatory bowel 
disease. Pharmacol Ther 2013; 137: 283-97. 
[64] Muzes G, Molnar B, Tulassay Z, Sipos F. Changes of the cytokine 
profile in inflammatory bowel diseases. World J Gastroenterol 
2012; 18: 5848-61. 
[65] Rubino SJ, Selvanantham T, Girardin SE, Philpott DJ. Nod-like 
receptors in the control of intestinal inflammation. Curr Opin 
Immunol 2012; 24: 398-404. 
[66] Zambetti LP, Laudisi F, Licandro G, Ricciardi-Castagnoli P, 
Mortellaro A. The rhapsody of NLRPs: master players of 
inflammation...and a lot more. Immunol Res 2012; 53: 78-90. 
[67] Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-
like receptors and their function. Nat Rev Immunol 2012; 12: 168-
79. 
[68] Arpaia N, Barton GM. The impact of Toll-like receptors on 
bacterial virulence strategies. Curr Opin Microbiol 2013; doi:pii: 
S1369-5274(12)00170-1. 10.1016/j.mib.2012.11.004. [Epub ahead 
of print] 
[69] Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen 
recognition. Int Immunol 2009; 21: 317-37. 
[70] Brown J, Wang H, Hajishengallis GN, Martin M. TLR-signaling 
networks: an integration of adaptor molecules, kinases, and cross-
talk. J Dent Res 2011; 90: 417-27. 
[71] Loo YM, Gale M, Jr. Immune signaling by RIG-I-like receptors. 
Immunity 2011; 34: 680-92. 
[72] Drummond RA, Saijo S, Iwakura Y, Brown GD. The role of 
Syk/CARD9 coupled C-type lectins in antifungal immunity. Eur J 
Immunol 2011; 41: 276-81. 
[73] Hardison SE, Brown GD. C-type lectin receptors orchestrate 
antifungal immunity. Nat Immunol 2012; 13: 817-22. 
[74] Jager S, Stange EF, Wehkamp J. Inflammatory bowel disease: an 
impaired barrier disease. Langenbecks Arch Surg 2013; 398: 1-12. 
[75] McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. 
Intestinal barrier dysfunction in inflammatory bowel diseases. 
Inflamm Bowel Dis 2009; 15: 100-13. 
[76] Salim SY, Soderholm JD. Importance of disrupted intestinal barrier 
in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 
362-81. 
[77] Turner JR. Intestinal mucosal barrier function in health and disease. 
Nat Rev Immunol 2009; 9: 799-809. 
[78] Soderholm JD, Streutker C, Yang PC, et al. Increased epithelial 
uptake of protein antigens in the ileum of Crohn's disease mediated 
by tumour necrosis factor alpha. Gut 2004; 53: 1817-24. 
[79] Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and 
distribution of claudin 2, 5 and 8 lead to discontinuous tight 
junctions and barrier dysfunction in active Crohn's disease. Gut 
2007; 56: 61-72. 
[80] Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls 
mucosal inflammation by regulating epithelial barrier function. 
Gastroenterology 2007; 132: 1359-74. 
[81] Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances 
ZO-1-associated intestinal epithelial barrier integrity via protein 
kinase C. Gastroenterology 2004; 127: 224-38. 
[82] Hiemstra IH, Bouma G, Geerts D, Kraal G, den Haan JM. Nod2 
improves barrier function of intestinal epithelial cells via 
enhancement of TLR responses. Mol Immunol 2012; 52: 264-72. 
[83] O'Hara JR, Feener TD, Fischer CD, Buret AG. Campylobacter 
jejuni disrupts protective Toll-like receptor 9 signaling in colonic 
epithelial cells and increases the severity of dextran sulfate sodium-
induced colitis in mice. Infect Immun 2012; 80: 1563-71. 
[84] Guo S, Al Sadi R, Said HM, Ma TY. Lipopolysaccharide Causes 
an Increase in Intestinal Tight Junction Permeability in vitro and in 
vivo by Inducing Enterocyte Membrane Expression and 
Localization of TLR-4 and CD14. Am J Pathol 2013; 182: 375-87. 
[85] Salzman NH. Paneth cell defensins and the regulation of the 
microbiome: detente at mucosal surfaces. Gut Microbes 2010; 1: 
401-6. 
[86] Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent 
regulation of innate and adaptive immunity in the intestinal tract. 
Science 2005; 307: 731-4. 
[87] Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) 
mutations in Crohn's disease are associated with diminished 
mucosal alpha-defensin expression. Gut 2004; 53: 1658-64. 
[88] Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell 
alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 
2005; 102: 18129-34. 
[89] Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, 
Radford-Smith GL. Reduced alpha-defensin expression is 
associated with inflammation and not NOD2 mutation status in 
ileal Crohn's disease. Gut 2008; 57: 903-10. 
[90] Vora P, Youdim A, Thomas LS, et al. Beta-defensin-2 expression 
is regulated by TLR signaling in intestinal epithelial cells. J 
Immunol 2004; 173: 5398-405. 
[91] Koon HW, Shih DQ, Chen J, et al. Cathelicidin signaling via the 
Toll-like receptor protects against colitis in mice. Gastroenterology 
2011; 141: 1852-63. 
[92] Caricilli AM, Picardi PK, de Abreu LL, et al. Gut microbiota is a 
key modulator of insulin resistance in TLR 2 knockout mice. PLoS 
Biol 2011; 9: e1001212. 
[93] Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome 
regulates colonic microbial ecology and risk for colitis. Cell 2011; 
145: 745-57. 
[94] Neurath MF, Travis SP. Mucosal healing in inflammatory bowel 
diseases: a systematic review. Gut 2012; 61: 1619-35. 
[95] Ey B, Eyking A, Gerken G, Podolsky DK, Cario E. TLR2 mediates 
gap junctional intercellular communication through connexin-43 in 
intestinal epithelial barrier injury. J Biol Chem 2009; 284: 22332-
43. 
[96] Fukata M, Abreu MT. Pathogen recognition receptors, cancer and 
inflammation in the gut. Curr Opin Pharmacol 2009; 9: 680-7. 
[97] Ungaro R, Fukata M, Hsu D, et al. A novel Toll-like receptor 4 
antagonist antibody ameliorates inflammation but impairs mucosal 
healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 
2009; 296: 1167-79. 
[98] Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, 
Kanneganti TD. The NLRP3 inflammasome protects against loss of 
epithelial integrity and mortality during experimental colitis. 
Immunity 2010; 32: 379-91. 
[99] Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell 
access to the intestinal lumen and bacterial clearance. Science 
2005; 307: 254-8. 
[100] Rutella S, Locatelli F. Intestinal dendritic cells in the pathogenesis 
of inflammatory bowel disease. World J Gastroenterol 2011; 17: 
3761-75. 
[101] Stagg AJ, Hart AL, Knight SC, Kamm MA. The dendritic cell: its 
role in intestinal inflammation and relationship with gut bacteria. 
Gut 2003; 52: 1522-9. 
[102] Hart AL, Al Hassi HO, Rigby RJ, et al. Characteristics of intestinal 
dendritic cells in inflammatory bowel diseases. Gastroenterology 
2005; 129: 50-65. 
[103] Ikeda Y, Akbar F, Matsui H, Onji M. Characterization of antigen-
presenting dendritic cells in the peripheral blood and colonic 
mucosa of patients with ulcerative colitis. Eur J Gastroenterol 
Hepatol 2001; 13: 841-50. 
[104] te Velde AA, van Kooyk Y, Braat H, et al. Increased expression of 
DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell 
populations in the colonic mucosa of patients with Crohn's disease. 
Eur J Immunol 2003; 33: 143-51. 
[105] Vuckovic S, Florin TH, Khalil D, et al. CD40 and CD86 
upregulation with divergent CMRF44 expression on blood 
dendritic cells in inflammatory bowel diseases. Am J Gastroenterol 
2001; 96: 2946-56. 
[106] Baumgart DC, Thomas S, Przesdzing I, et al. Exaggerated 
inflammatory response of primary human myeloid dendritic cells to 
14    Current Pharmaceutical Design, 2014, Vol. 20, No. 00 Gyires et al. 
lipopolysaccharide in patients with inflammatory bowel disease. 
Clin Exp Immunol 2009; 157: 423-36. 
[107] Iliev ID, Spadoni I, Mileti E, et al. Human intestinal epithelial cells 
promote the differentiation of tolerogenic dendritic cells. Gut 2009; 
58: 1481-89. 
[108] Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. 
Nat Rev Immunol 2005; 5: 953-64. 
[109] Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 
The chemokine system in diverse forms of macrophage activation 
and polarization. Trends Immunol 2004; 25: 677-86. 
[110] Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage 
cytokine secretion underlies impaired acute inflammation and 
bacterial clearance in Crohn's disease. J Exp Med 2009; 206: 1883-
97. 
[111] Kamada N, Hisamatsu T, Okamoto S, et al. Unique CD14 intestinal 
macrophages contribute to the pathogenesis of Crohn disease via 
IL-23/IFN-gamma axis. J Clin Invest 2008; 118: 2269-80. 
[112] Nishihira J. Molecular function of macrophage migration inhibitory 
factor and a novel therapy for inflammatory bowel disease. Ann N 
Y Acad Sci 2012; 1271: 53-7. 
[113] Roger T, Delaloye J, Chanson AL, Giddey M, Le Roy D, Calandra 
T. Macrophage Migration Inhibitory Factor Deficiency Is 
Associated With Impaired Killing of Gram-Negative Bacteria by 
Macrophages and Increased Susceptibility to Klebsiella 
pneumoniae Sepsis. J Infect Dis 2013; 207: 331-9. 
[114] Roger T, David J, Glauser MP, Calandra T. MIF regulates innate 
immune responses through modulation of Toll-like receptor 4. 
Nature 2001; 414: 920-4. 
[115] Ohkawara T, Nishihira J, Takeda H, et al. Amelioration of dextran 
sulfate sodium-induced colitis by anti-macrophage migration 
inhibitory factor antibody in mice. Gastroenterology 2002; 123: 
256-70. 
[116] Murakami H, Akbar SM, Matsui H, Onji M. Macrophage migration 
inhibitory factor in the sera and at the colonic mucosa in patients 
with ulcerative colitis: clinical implications and pathogenic 
significance. Eur J Clin Invest 2001; 31: 337-43. 
[117] Takahashi N, Nishihira J, Sato Y, et al. Involvement of 
macrophage migration inhibitory factor (MIF) in the mechanism of 
tumor cell growth. Mol Med 1998; 4: 707-14. 
[118] Bouma G, Strober W. The immunological and genetic basis of 
inflammatory boweldisease. Nat Rev Immunol 2003; 3: 521-33. 
[119] Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key 
effector Th2 cytokine in ulcerative colitis that affects epithelial 
tight junctions, apoptosis, and cell restitution. Gastroenterology 
2005; 129: 550-64. 
[120] Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper 
cell predominance and interleukin-12 expression in the gut of 
patients with Crohn's disease. Am J Pathol 1997; 150: 823-32. 
[121] Manel N, Unutmaz D, Littman DR. The differentiation of human 
T(H)-17 cells requires transforming growth factor-beta and 
induction of the nuclear receptor RORgammat. Nat Immunol 2008; 
9: 641-9. 
[122] Monteleone I, Sarra M, Pallone F, Monteleone G. Th17-related 
cytokines in inflammatory bowel diseases: friends or foes? Curr 
Mol Med 2012; 12: 592-7. 
[123] Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med 
2007; 13: 26-8. 
[124] Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. 
Critical role of IL-17 receptor signaling in acute TNBS-induced 
colitis. Inflamm Bowel Dis 2006; 12: 382-8. 
[125] Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria 
T(H)17 cell differentiation. Nature 2008; 455: 808-12. 
[126] Ivanov II, Frutos RL, Manel N, et al. Specific microbiota direct the 
differentiation of IL-17-producing T-helper cells in the mucosa of 
the small intestine. Cell Host Microbe 2008; 4: 337-49. 
[127] Uematsu S, Fujimoto K, Jang MH, et al. Regulation of humoral 
and cellular gut immunity by lamina propria dendritic cells 
expressing Toll-like receptor 5. Nat Immunol 2008; 9: 769-76. 
[128] Hall JA, Bouladoux N, Sun CM, et al. Commensal DNA limits 
regulatory T cell conversion and is a natural adjuvant of intestinal 
immune responses. Immunity 2008; 29: 637-49. 
[129] van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. 
Stimulation of the intracellular bacterial sensor NOD2 programs 
dendritic cells to promote interleukin-17 production in human 
memory T cells. Immunity 2007; 27: 660-9. 
[130] Rahman MK, Midtling EH, Svingen PA, et al. The pathogen 
recognition receptor NOD2 regulates human FOXP3+ T cell 
survival. J Immunol 2010; 184: 7247-56. 
[131] Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. 
Integration of B cell responses through Toll-like receptors and 
antigen receptors. Nat Rev Immunol 2012; 12: 282-94. 
[132] Qin J, Li R, Raes J, Arumugam M, et al. A human gut microbial 
gene catalogue established by metagenomic sequencing. Nature 
2010; 464: 59-65. 
[133] Human Microbiome Project Consortium. Structure, function and 
diversity of the healthy human microbiome. Nature 2012; 486: 207-
14. 
[134] Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota 
composition correlates with diet and health in the elderly. Nature 
2012; 488: 178-84. 
[135] Aitken JD, Gewirtz AT. Gut microbiota in 2012: Toward 
understanding and manipulating the gut microbiota. Nat Rev 
Gastroenterol Hepatol 2013; 10: 72-4. 
[136] Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota 
metabolic interactions. Science 2012; 336: 1262-7. 
[137] Tremaroli V, Backhed F. Functional interactions between the gut 
microbiota and host metabolism. Nature 2012; 489: 242-9. 
[138] Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia 
coli and Crohn's disease. Curr Opin Gastroenterol 2007; 23: 16-20. 
[139] Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium 
subspecies paratuberculosis and Crohn's disease: a systematic 
review and meta-analysis. Lancet Infect Dis 2007; 7: 607-13. 
[140] Flanagan P, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis 
of inflammatory bowel disease. Biochem Soc Trans 2011; 39: 
1067-72. 
[141] Prantera C, Scribano ML. Antibiotics and probiotics in 
inflammatory bowel disease: why, when, and how. Curr Opin 
Gastroenterol 2009; 25: 329-33. 
[142] Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum 
antibiotic therapy in patients with active inflammatory bowel 
disease. Exp Ther Med 2012; 4: 1051-6. 
[143] Deuring JJ, de Haar C, Kuipers EJ, Peppelenbosch MP, van der 
Woude CJ. The cell biology of the intestinal epithelium and its 
relation to inflammatory bowel disease. Int J Biochem Cell Biol 
2013; 45: 798-806. 
[144] Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-
acid dysmetabolism and gut inflammation in inflammatory bowel 
diseases. Gut 2013; 62: 531-9. 
[145] Li Q, Wang C, Tang C, Li N, Li J. Molecular-phylogenetic 
characterization of the microbiota in ulcerated and non-ulcerated 
regions in the patients with Crohn's disease. PLoS One 2012; 7: 
e34939. 
[146] Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced 
diversity of faecal microbiota in Crohn's disease revealed by a 
metagenomic approach. Gut 2006; 55: 205-11. 
[147] Sha S, Xu B, Wang X, et al. The biodiversity and composition of 
the dominant fecal microbiota in patients with inflammatory bowel 
disease. Diagn Microbiol Infect Dis 2013; 75: 245-51. 
[148] Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium 
prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15: 
1183-9. 
[149] Atarashi K, Tanoue T, Shima T, et al. Induction of colonic 
regulatory T cells by indigenous Clostridium species. Science 
2011; 331: 337-41. 
[150] Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic 
health: fermentation and short chain fatty acids. J Clin 
Gastroenterol 2006; 40: 235-43. 
[151] Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of 
Lactobacillus GG in maintaining remission of ulcerative colitis. 
Aliment Pharmacol Ther 2006; 23:1567-74. 
[152] Macho FE, Valenti V, Rockel C, et al. Anti-inflammatory capacity 
of selected lactobacilli in experimental colitis is driven by NOD2-
mediated recognition of a specific peptidoglycan-derived 
muropeptide. Gut 2011; 60: 1050-9. 
[153] von Schillde MA, Hormannsperger G, Weiher M, et al. Lactocepin 
secreted by Lactobacillus exerts anti-inflammatory effects by 
selectively degrading proinflammatory chemokines. Cell Host 
Microbe 2012; 11: 387-96. 
[154] Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. Mucosal and invading 
bacteria in patients with inflammatory bowel disease compared 
with controls. Scand J Gastroenterol 2002; 37: 1034-41. 
Gut Inflammation: Current Update on Pathophysiology Current Pharmaceutical Design, 2014, Vol. 20, No. 00    15 
[155] Lucke K, Miehlke S, Jacobs E, Schuppler M. Prevalence of 
Bacteroides and Prevotella spp. in ulcerative colitis. J Med 
Microbiol 2006; 55: 5-24. 
[156] Wright DP, Rosendale DI, Robertson AM. Prevotella enzymes 
involved in mucin oligosaccharide degradation and evidence for a 
small operon of genes expressed during growth on mucin. FEMS 
Microbiol Lett 2000; 190: 73-9. 
[157] Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis 
factor prevents intestinal inflammatory disease. Nature 2008; 453: 
620-5. 
[158] Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway 
establishes colonization by a commensal of the human microbiota. 
Science 2011; 332: 974-7. 
[159] Ruseler-van Embden JG, Both-Patoir HC. Anaerobic gram-
negative faecal flora in patients with Crohn's disease and healthy 
subjects. Antonie Van Leeuwenhoek 1983; 49: 125-32. 
[160] Philippe D, Favre L, Foata F, et al. Bifidobacterium lactis 
attenuates onset of inflammation in a murine model of colitis. 
World J Gastroenterol 2011; 17: 459-69. 
[161] Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy 
(Bifidobacterium longum/Synergy 1) initiates resolution of 
inflammation in patients with active ulcerative colitis: a 
randomised controlled pilot trial. Gut 2005; 54: 242-9. 
[162] Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. 
Remission induction and maintenance effect of probiotics on 
ulcerative colitis: a meta-analysis. World J Gastroenterol 2010; 16: 
1908-15. 
[163] Steed H, Macfarlane GT, Blackett KL, et al. Clinical trial: the 
microbiological and immunological effects of synbiotic 
consumption - a randomized double-blind placebo-controlled study 
in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-
83. 
[164] Jeon SG, Kayama H, Ueda Y, et al. Probiotic Bifidobacterium 
breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 
2012; 8: e1002714. 
[165] Wine E, Ossa JC, Gray-Owen SD, Sherman PM. Adherent-invasive 
Escherichia coli, strain LF82 disrupts apical junctional complexes 
in polarized epithelia. BMC Microbiol 2009; 9: 180-9. 
[166] Denizot J, Sivignon A, Barreau F, et al. Adherent-invasive 
Escherichia coli induce claudin-2 expression and barrier defect in 
CEABAC10 mice and Crohn's disease patients. Inflamm Bowel 
Dis 2012; 18: 294-304. 
[167] Samba-Louaka A, Nougayrede JP, Watrin C, Oswald E, Taieb F. 
The enteropathogenic Escherichia coli effector Cif induces delayed 
apoptosis in epithelial cells. Infect Immun 2009; 77: 5471-7. 
[168] Munch A, Strom M, Soderholm JD. Dihydroxy bile acids increase 
mucosal permeability and bacterial uptake in human colon 
biopsies. Scand J Gastroenterol 2007; 42: 1167-74. 
[169] Stenman LK, Holma R, Eggert A, Korpela R. A novel mechanism 
for gut barrier dysfunction by dietary fat: epithelial disruption by 
hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol 
2013; 304: 227-34. 
[170] Muegge BD, Kuczynski J, Knights D, et al. Diet drives 
convergence in gut microbiome functions across mammalian 
phylogeny and within humans. Science 2011; 332: 970-4. 
[171] Triantafillidis JK, Merikas E, Gikas A. Psychological factors and 
stress in inflammatory bowel disease. Expert Rev Gastroenterol 
Hepatol 2013; 7: 225-38. 
[172] Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced 
taurocholic acid promotes pathobiont expansion and colitis in Il10-
/- mice. Nature 2012; 487: 104-8. 
[173] Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced 
gut microbiota exacerbates inflammation and obesity in mice via 
the TLR4 signaling pathway. PLoS One 2012; 7: e47713. 
[174] Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect 
induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-
defensin beta2 innate immune pathway defective in Crohn disease. 
J Biol Chem 2010; 285: 2227-31. 
[175] Jones DT, Osterman MT, Bewtra M, Lewis JD. Passive smoking 
and inflammatory bowel disease: a meta-analysis. Am J 
Gastroenterol 2008; 103: 2382-93. 
[176] Kaplan GG, Hubbard J, Korzenik J, et al. The inflammatory bowel 
diseases and ambient air pollution: a novel association. Am J 
Gastroenterol 2010; 105: 2412-9. 
[177] Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D. 
Inflammatory bowel disease and domestic hygiene in infancy. 
Lancet 1994; 343: 766-7. 
[178] Weinstock JV, Elliott DE. Helminths and the IBD hygiene 
hypothesis. Inflamm Bowel Dis 2009; 15: 128-33. 
[179] Elliott DE, Weinstock JV. Where are we on worms? Curr Opin 
Gastroenterol 2012; 28: 551-6. 
[180] Weinstock JV, Elliott DE. Translatability of helminth therapy in 
inflammatory bowel diseases. Int J Parasitol 2013; 43: 245-51. 
[181] Walk ST, Blum AM, Ewing SA, Weinstock JV, Young VB. 
Alteration of the murine gut microbiota during infection with the 
parasitic helminth Heligmosomoides polygyrus. Inflamm Bowel 
Dis 2010; 16: 1841-9. 
[182] Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based 
systematic review on medical therapies for inflammatory bowel 
disease. Am J Gastroenterol 2011; 106 (Suppl 1): 2-25. 
[183] Keyashian K, Annunziata ML, Sakuraba A, Hanauer S. 
Management of inflammatory bowel disease: past, present and 
future. Expert Rev Clin Immunol 2012; 8: 303-5. 
[184] Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe 
ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 
330: 1841-5. 
[185] Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study 
of chimeric monoclonal antibody cA2 to tumor necrosis factor 
alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N 
Engl J Med 1997; 337: 1029-35. 
[186] Clark M, Colombel JF, Feagan BC, et al.Proceedings of the 
American gastroenterological association consensus development 
conference on the use of biologics in the treatment of inflammatory 
bowel disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-
39. 
[187] Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, 
Moayyedi P. Efficacy of biological therapies in inflammatory 
bowel disease: systematic review and meta-analysis. Am J 
Gastroenterol 2011; 106: 644-59. 
[188] Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor 
necrosis factor antagonist mechanisms of action: a comprehensive 
review. Pharmacol Ther 2008; 117: 244-79. 
[189] Desilva S, Kaplan G, Panaccione R. Sequential therapies for 
Crohn's disease: optimizing conventional and biologic strategies. 
Rev Gastroenterol Disord 2008; 8: 109-16. 
[190] Schmidt KJ, Buning J, Jankowiak C, Lehnert H, Fellermann K. 
Crohn's targeted therapy: myth or real goal? Curr Drug Discov 
Technol 2009; 6: 290-8. 
[191] Dignass A, Van Assche G, Lindsay JO, et al. The second European 
evidence-based Consensus on the diagnosis and management of 
Crohn's disease: Current management. J Crohns Colitis 2010; 4: 
28-62. 
[192] Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, 
Gendre JP. Impact of the increasing use of immunosuppressants in 
Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 
237-41. 
[193] Gionchetti P, Calabrese C, Tambasco R, et al. Role of conventional 
therapies in the era of biological treatment in Crohn's disease. 
World J Gastroenterol 2011; 17: 1797-1806. 
[194] Fasci SF, Aratari A, Margagnoni G, Doddato MT, Papi C. Early 
treatment in Crohn's disease: do we have enough evidence to 
reverse the therapeutic pyramid? J Gastrointestin Liver Dis 2012; 
21: 67-73. 
[195] Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, 
Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and 
the risk of serious infections and malignancies: systematic review 
and meta-analysis of rare harmful effects in randomized controlled 
trials. JAMA 2006; 295: 2275-85. 
[196] Semerano L, Assier E, Delavallee L, Boissier MC. Kinoid of 
human tumor necrosis factor-alpha for rheumatoid arthritis. Expert 
Opin Biol Ther 2011; 11: 545-50. 
[197] Paul-Clark MJ, George PM, Gatheral T, et al. Pharmacology and 
therapeutic potential of pattern recognition receptors. 2012; 135: 
200-15. 
[198] Levine B, Kroemer G. Autophagy in the pathogenesis of disease. 
Cell 2008; 132: 27-42. 
[199] Kuma A, Mizushima N, Ishihara N, Ohsumi Y. Formation of the 
approximately 350-kDa Apg12-Apg5.Apg16 multimeric complex, 
mediated by Apg16 oligomerization, is essential for autophagy in 
yeast. J Biol Chem 2002; 277(21):18619-18625. 
16    Current Pharmaceutical Design, 2014, Vol. 20, No. 00 Gyires et al. 
[200] Lesage S, Zouali H, Cézard JP, et al. CARD15/NOD2 mutational 
analysis and genotype-phenotype correlation in 612 patients with 
inflammatory bowel disease. Am J Hum Genet. 2002; 70: 845-57. 
[201] Fowler EV, Doecke J, Simms LA, et al. ATG16L1 T300A shows 
strong associations with disease subgroups in a large Australian 
IBD population: further support for significant disease 
heterogeneity. Am J Gastroenterol 2008; 103: 2519-26. 
[202] Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ. Impaired 
autophagy of an intracellular pathogen induced by a Crohn's 
disease associated ATG16L1 variant. PLoS One 2008; 3: e3391. 
[203] Cario E, Podolsky DK. Differential alteration in intestinal epithelial 
cell expression of toll-like receptor 3 (TLR3) and TLR4 in 
inflammatory bowel disease. Infect Immun 2000; 68: 7010-7. 
[204] Obermeier F, Dunger N, Strauch UG, et al. Contrasting activity of 
cytosin-guanosin dinucleotide oligonucleotides in mice with 
experimental colitis. Clin Exp Immunol 2003; 134: 217-24. 
[205] Vijay-Kumar M, Wu H, Aitken J, et al. Activation of toll-like 
receptor 3 protects against DSS-induced acute colitis. Inflamm 
Bowel Dis 2007; 13: 856-64. 
[206] Watanabe T, Asano N, Murray PJ, et al. Muramyl dipeptide 
activation of nucleotide-binding oligomerization domain 2 protects 
mice from experimental colitis. J Clin Invest 2008; 118: 545-559. 
[207] Fukata M, Abreu MT. Pathogen recognition receptors, cancer and 
inflammation in the gut. Curr Opin Pharmacol 2009; 9: 680-7. 
[208] Hausmann M, Kiessling S, Mestermann S, et al. Toll-like receptors 
2 and 4 are up-regulated during intestinal inflammation. 
Gastroenterology 2002; 122: 1987-2000. 
[209] Ungaro R, Fukata M, Hsu D, et al. A novel Toll-like receptor 4 
antagonist antibody ameliorates inflammation but impairs mucosal 
healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 
2009; 296: 1167-79. 
[210] Zhang S, Cheng K, Wang X, Yin H. Selection, synthesis, and anti-
inflammatory evaluation of the arylidene malonate derivatives as 
TLR4 signaling inhibitors. Bioorg Med Chem 2012; 20: 6073-9. 
[211] Bosani M, Ardizzone S, Porro GB. Biologic targeting in the 
treatment of inflammatory bowel diseases. Biologics 2009; 3: 77-
97. 
[212] Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress 
systemic and mucosal immune activation to control intestinal 
inflammation. Immunol Rev 2006; 212: 256-71. 
[213] Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 
2009; 361: 2066-78. 
[214] Ahluwalia JP. Immunotherapy in inflammatory bowel disease. Med 
Clin North Am 2012; 96: 525-44. 
[215] Siegmund B. Targeted therapies in inflammatory bowel disease. 
Dig Dis. 2009; 27: 465-9. 
[216] Magro F, Portela F. Management of inflammatory bowel disease 
with infliximab and other anti-tumor necrosis factor alpha 
therapies. BioDrugs 2010; 24 (Suppl 1): 3-14. 
[217] Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC. Mechanisms 
and efficacy of immunobiologic therapies for inflammatory bowel 
diseases. Int Rev Immunol 2010; 29: 4-37. 
[218] Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch 
W. Review article: the role of anti-TNF in the management of 
ulcerative colitis - past, present and future. Aliment Pharmacol 
Ther 2013; doi: 10.1111/apt.12284. [Epub ahead of print] 
[219] Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour 
necrosis factor receptors: structure and function. Trends Cell Biol 
1995; 5: 392-9. 
[220] Papadakis KA, Targan SR. Tumor necrosis factor: biology and 
therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57. 
[221] Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T 
cells to multiple apoptotic signals is associated with a Bcl-2/Bax 
mucosal imbalance. J Immunol 1999; 163: 1081-90. 
[222] Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, 
Kucharzik T. Infliximab induces apoptosis in monocytes from 
patients with chronic active Crohn's disease by using a caspase-
dependent pathway. Gastroenterology 2001; 121: 1145-57. 
[223] ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer 
SJ. Infliximab treatment induces apoptosis of lamina propria T 
lymphocytes in Crohn's disease. Gut 2002; 50: 206-11. 
[224] Doering J, Begue B, Lentze MJ, et al. Induction of T lymphocyte 
apoptosis by sulphasalazine in patients with Crohn's disease. Gut 
2004; 53: 1632-8. 
[225] Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease 
and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 
3: 390-407. 
[226] Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is 
the molecular target of azathioprine in primary human CD4+ T 
lymphocytes. J Clin Invest 2003; 111: 1133-45. 
[227] Panaccione R, Loftus EV, Jr., Binion D, et al. Efficacy and safety 
of adalimumab in Canadian patients with moderate to severe 
Crohn's disease: results of the Adalimumab in Canadian SubjeCts 
with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J 
Gastroenterol 2011; 25: 419-25. 
[228] Trinder MW, Lawrance IC. Efficacy of adalimumab for the 
management of inflammatory bowel disease in the clinical setting. 
J Gastroenterol Hepatol 2009; 24: 1252-7. 
[229] Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab 
induces and maintains clinical remission in patients with moderate-
to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65. 
[230] Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, 
placebo-controlled trial of certolizumab pegol (CDP870) for 
treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18. 
[231] Smith LS, Nelson M, Dolder CR. Certolizumab pegol: a TNF-
{alpha} antagonist for the treatment of moderate-to-severe Crohn's 
disease. Ann Pharmacother 2010; 44: 333-42. 
[232] Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol 
for active Crohn's disease: a placebo-controlled, randomized trial. 
Clin Gastroenterol Hepatol 2011; 9: 670-8. 
[233] Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active 
Crohn's disease: a randomized, double-blind, placebo-controlled 
trial. Gastroenterology 2001; 121: 1088-94. 
[234] Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. 
Treatment of ulcerative colitis with an engineered human anti-
TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997; 11: 
1031-5. 
[235] Rogler G, Michetti PF, Kruger FC, et al. Active therapeutic 
immunization against TNF with a TNF-kinoid in Crohn’s disease 
patients: a phase 1-2 study. Gastroenterology 2010; 138 (Suppl 1): 
517. 
[236] Hodgkinson L. Digestive Disease Week 2010. Turning Science into 
Medicine--part 2. IDrugs. 2010; 13: 424-6. 
[237] Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans 
signaling suppresses T-cell resistance against apoptosis in chronic 
intestinal inflammation: evidence in crohn disease and 
experimental colitis in vivo. Nat Med 2000; 6: 583-8. 
[238] Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required 
for the development of Th1 cell-mediated murine colitis. J 
Immunol 2000; 164: 4878-82. 
[239] Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor 
antibody, tocilizumab. Handb Exp Pharmacol 2008; 181: 151-60. 
[240] Venkiteshwaran A. Tocilizumab. MAbs 2009; 1: 432-8. 
[241] Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a 
human anti-interleukin-6 receptor monoclonal antibody in active 
Crohn's disease. Gastroenterology 2004; 126: 989-96. 
[242] Nishimoto N. Clinical studies in patients with Castleman's disease, 
Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev 
Allergy Immunol 2005; 28: 221-30. 
[243] Bouma G, Strober W. The immunological and genetic basis of 
inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-33. 
[244] Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key 
effector Th2 cytokine in ulcerative colitis that affects epithelial 
tight junctions, apoptosis, and cell restitution. Gastroenterology 
2005; 129: 550-64. 
[245] Rosen MJ, Frey MR, Washington MK, et al. STAT6 activation in 
ulcerative colitis: a new target for prevention of IL-13-induced 
colon epithelial cell dysfunction. Inflamm Bowel Dis 2011; 17: 
2224-34. 
[246] US National Institutes of Health Clinical Trials [homepage on the 
Internet] [cited 2011] Available from: 
http://www.clinicaltrials.gov 
[247] Mannon P, Reinisch W. Interleukin 13 and its role in gut defence 
and inflammation. Gut 2012; 12: 1765-73. 
[248] Waetzig GH, Seegert D, Nikolaus S, Rosenstiel P, Sfikas N, 
Schreiber S. Differential activity and expression of mitogen-
activated protein kinases in inflammatory bowel disease. 
Gastroenterology 2001; 120 (Suppl 1): A522. 
Gut Inflammation: Current Update on Pathophysiology Current Pharmaceutical Design, 2014, Vol. 20, No. 00    17 
[249] Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-
activated MAP kinases induces clinical improvement in moderate 
to severe Crohn's disease. Gastroenterology 2002; 122: 7-14. 
[250] Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-
activated protein kinase inhibition with BIRB 796 for active 
Crohn's disease: a randomized, double-blind, placebo-controlled 
trial. Clin Gastroenterol Hepatol 2006; 4: 325-34. 
[251] Zu YL, Qi J, Gilchrist A, et al. p38 mitogen-activated protein 
kinase activation is required for human neutrophil function 
triggered by TNF-alpha or FMLP stimulation. J Immunol 1998; 
160: 1982-9. 
[252] Pallone F, Fina D, Caruso R, Monteleone G. Role of IL-21 in 
inflammatory bowel disease. Expert Rev Clin Immunol 2010; 6: 
537-41. 
[253] Ajdukovic J, Tonkic A, Salamunic I, Hozo I, Simunic M, Bonacin 
D. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative 
colitis. Hepatogastroenterology 2010; 57: 1442-4. 
[254] Ludwiczek O, Kaser A, Novick D, Dinarello CA, Rubinstein M, 
Tilg H. Elevated systemic levels of free interleukin-18 (IL-18) in 
patients with Crohn's disease. Eur Cytokine Netw 2005; 16: 27-33. 
[255] Hueber W, Sands BE, Vandemeulebroecke M, et al. Inhibition of 
IL-17A by secukinumab is ineffective for Crohn’s disease (CD). 
Proceedings of the 6th Congress of ECCO 2011. Stockholm, 
September 25-26th 2011; European Cancer Organisation. 
[256] Herrlinger KR, Diculescu M, Fellermann K, et al. Efficacy, safety 
and tolerability of vidofludimus in patients with inflammatory 
bowel disease: The ENTRANCE study. J Crohns Colitis 2013; pii: 
S1873-9946(12)00417-5. doi: 10.1016/j.crohns.2012.09.016. [Epub 
ahead of print] 
[257] Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of 
CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for 
the treatment of autoimmune diseases and organ transplant 
rejection. J Med Chem 2010; 53: 8468-84. 
[258] Sandborn WJ, Ghosh S, Panes J, et al. Phase 2 randomized study of 
CP-690,550, an oral janus kinase inhibitor, in active Crohn’s 
disease. Proceedings of the Digestive Disease Week 2011; 
Chicago, Illinois, May 7-10, 2011; 140: 745. 
[259] Sandborn WJ, Ghosh S, Panes J, et al. Phase 2 study of CP- 
690,550, and oral janus kinase inhibitor, in active ulcerative colitis. 
Proceedings of the Digestive Disease Week 2011; Chicago, Illinois, 
May 7-10, 2011; 140: 594. 
[260] Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a 
humanised monoclonal antibody to the interleukin 2 receptor 
(CD25), for the treatment of moderately to severely active 
ulcerative colitis: a randomised, double blind, placebo controlled, 
dose ranging trial. Gut 2006; 55: 1568-74. 
[261] Sands BE, Sandborn WJ, Creed TJ, et al. Basiliximab does not 
increase efficacy of corticosteroids in patients with steroid-
refractory ulcerative colitis. Gastroenterology 2012; 143: 356-64. 
[262] Maloy KJ. The Interleukin-23 / Interleukin-17 axis in intestinal 
inflammation. J Intern Med 2008; 263: 584-90. 
[263] Monteleone G, Fina D, Caruso R, Pallone F. New mediators of 
immunity and inflammation in inflammatory bowel disease. Curr 
Opin Gastroenterol 2006; 22: 361-4. 
[264] Guan Q, Ma Y, Hillman CL, et al. Targeting IL-12/IL-23 by 
employing a p40 peptide-based vaccine ameliorates TNBS-induced 
acute and chronic murine colitis. Mol Med 2011; 17: 646-56. 
[265] Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody 
for active Crohn's disease. N Engl J Med 2004; 351: 2069-79. 
[266] Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and 
maintenance therapy in refractory Crohn's disease. N Engl J Med 
2012; 367: 1519-28. 
[267] Panaccione R, Sandborn WJ, Gordon G, et al. Briakinumab 
(ABT874) for treatment of Crohn’s disease. Proceedings of the 
United European Gastroenterology Week 2010; Barcelona, Spain, 
October 23-27, 2011; 59: OP051D. 
[268] Sands BE, Jacobson EW, Sylwestrowicz T, et al. Randomized, 
double-blind, placebo-controlled trial of the oral interleukin-12/23 
inhibitor apilimod mesylate for treatment of active Crohn's disease. 
Inflamm Bowel Dis 2010; 16: 1209-18. 
[269] Rutgeerts P, Reinisch W, Colombel JF, et al. Preliminary results of 
a phase I/II study of Huzaf, an anti-IFN-monoclonal antibody, in 
patients with moderate to severe active Crohn’s disease. 
Gastroenterology 2002; 122: 61. 
[270] Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in 
moderate to severe Crohn's disease: a phase 2, randomized, double-
blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 
2010; 16: 233-42. 
[271] Kozuch PL, Hanauer SB. General principles and pharmacology of 
biologics in inflammatory bowel disease. Gastroenterol Clin North 
Am 2006; 35: 757-73. 
[272] Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. 
Monoclonal antibodies specific for beta 7 integrin and mucosal 
addressin cell adhesion molecule-1 (MAdCAM-1) reduce 
inflammation in the colon of scid mice reconstituted with 
CD45RBhigh CD4+ T cells. J Immunol 1997; 158: 2099-106. 
[273] Plevy S, Salzberg B, Van Assche G, et al. A phase I study of 
visilizumab, a humanized anti-CD3 monoclonal antibody, in severe 
steroid-refractory ulcerative colitis. Gastroenterology 2007; 133: 
1414-22. 
[274] Baumgart DC, Targan SR, Dignass AU, et al. Prospective 
randomized open-label multicenter phase I/II dose escalation trial 
of visilizumab (HuM291) in severe steroid-refractory ulcerative 
colitis. Inflamm Bowel Dis 2010; 16: 620-9. 
[275] Sandborn WJ, Colombel JF, Frankel M, et al. Anti-CD3 antibody 
visilizumab is not effective in patients with intravenous 
corticosteroid-refractory ulcerative colitis. Gut 2010; 59: 1485-92. 
[276] Wood NJ. IBD: Visilizumab not useful for intravenous steroid-
refractory ulcerative colitis. Nat Rev Gastroenterol Hepatol 2011; 
8: 3. 
[277] Dumont FJ. Idec-131. Idec/eisai. Curr Opin Investig Drugs 2002; 3: 
725-34. 
[278] Hemler ME, Huang C, Takada Y, Schwarz L, Strominger JL, 
Clabby ML. Characterization of the cell surface heterodimer VLA-
4 and related peptides. J Biol Chem 1987; 262: 11478-85. 
[279] Farstad IN, Halstensen TS, Kvale D, Fausa O, Brandtzaeg P. 
Topographic distribution of homing receptors on B and T cells in 
human gut-associated lymphoid tissue: relation of L-selectin and 
integrin alpha 4 beta 7 to naive and memory phenotypes. Am J 
Pathol 1997; 150: 187-99. 
[280] Goto A, Arimura Y, Shinomura Y, Imai K, Hinoda Y. Antisense 
therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced 
murine colitis. Inflamm Bowel Dis 2006; 12: 758-65. 
[281] Sans M, Panes J, Ardite E, et al. VCAM-1 and ICAM-1 mediate 
leukocyte-endothelial cell adhesion in rat experimental colitis. 
Gastroenterology 1999; 116: 874-83. 
[282] Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active 
Crohn's disease. N Engl J Med 2003; 348: 24-32. 
[283] MacDonald JK, McDonald JW. Natalizumab for induction of 
remission in Crohn's disease. Cochrane Database Syst Rev 2007; 
(1): CD006097. 
[284] Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, 
Moayyedi P. Efficacy of biological therapies in inflammatory 
bowel disease: systematic review and meta-analysis. Am J 
Gastroenterol 2011; 106: 644-59. 
[285] Kappos L, Bates D, Edan G, et al. Natalizumab treatment for 
multiple sclerosis: updated recommendations for patient selection 
and monitoring. Lancet Neurol 2011; 10: 745-58. 
[286] Tilg H, Kaser A. Vedolizumab, a humanized mAb against the 
alpha4beta7 integrin for the potential treatment of ulcerative colitis 
and Crohn's disease. Curr Opin Investig Drugs 2010; 11: 1295-304. 
[287] Mosli MH, Feagan BG. Vedolizumab for Crohn's disease. Expert 
Opin Biol Ther 2013; 13: 455-63. 
[288] Marsal J, Agace WW. Targeting T-cell migration in inflammatory 
bowel disease. J Intern Med 2012; 272: 411-29. 
[289] Bennett CF, Kornbrust D, Henry S, et al. An ICAM-1 antisense 
oligonucleotide prevents and reverses dextran sulfate sodium-
induced colitis in mice. J Pharmacol Exp Ther 1997; 280: 988-
1000. 
[290] Taniguchi T, Tsukada H, Nakamura H, et al. Effects of the anti-
ICAM-1 monoclonal antibody on dextran sodium sulphate-induced 
colitis in rats. J Gastroenterol Hepatol 1998; 13: 945-9. 
[291] Philpott JR, Miner PB, Jr. Antisense inhibition of ICAM-1 
expression as therapy provides insight into basic inflammatory 
pathways through early experiences in IBD. Expert Opin Biol Ther 
2008; 8: 1627-32. 
[292] Sandborn WJ, Faubion WA. Biologics in inflammatory bowel 
disease: how much progress have we made? Gut 2004; 53: 1366-
73. 
[293] Fukuzawa H, Sawada M, Kayahara T, et al. Identification of GM-
CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys 
Res Commun 2003; 312: 897-902. 
18    Current Pharmaceutical Design, 2014, Vol. 20, No. 00 Gyires et al. 
[294] Ramsay RG, Micallef SJ, Williams B, et al. Colony-stimulating 
factor-1 promotes clonogenic growth of normal murine colonic 
crypt epithelial cells in vitro. J Interferon Cytokine Res 2004; 24: 
416-27. 
[295] Bernasconi E, Favre L, Maillard MH, et al. Granulocyte-
macrophage colony-stimulating factor elicits bone marrow-derived 
cells that promote efficient colonic mucosal healing. Inflamm 
Bowel Dis 2010; 16: 428-41. 
[296] Sainathan SK, Hanna EM, Gong Q, et al. Granulocyte macrophage 
colony-stimulating factor ameliorates DSS-induced experimental 
colitis. Inflamm Bowel Dis 2008; 14: 88-99. 
[297] Korzenik JR, Dieckgraefe BK. An open-labelled study of 
granulocyte colony-stimulating factor in the treatment of active 
Crohn's disease. Aliment Pharmacol Ther 2005; 21: 391-400. 
[298] Krishnan K, Arnone B, Buchman A. Intestinal growth factors: 
potential use in the treatment of inflammatory bowel disease and 
their role in mucosal healing. Inflamm Bowel Dis 2011; 17: 410-
22. 
[299] Moran CJ, Walters TD, Guo CH, et al. IL-10R Polymorphisms Are 
Associated with Very-early-onset Ulcerative Colitis. Inflamm 
Bowel Dis 2013; 19: 115-23. 
[300] Buruiana FE, Sola I, Alonso-Coello P. Recombinant human 
interleukin 10 for induction of remission in Crohn's disease. 
Cochrane Database Syst Rev 2010; (11): CD005109. 
[301] Trepicchio WL, Bozza M, Pedneault G, Dorner AJ. Recombinant 
human IL-11 attenuates the inflammatory response through down-
regulation of proinflammatory cytokine release and nitric oxide 
production. J Immunol 1996; 157: 3627-34. 
[302] Qiu BS, Pfeiffer CJ, Keith JC, Jr. Protection by recombinant human 
interleukin-11 against experimental TNB-induced colitis in rats. 
Dig Dis Sci 1996; 41: 1625-30. 
[303] Gibson DL, Montero M, Ropeleski MJ, Bergstrom KS, Ma C, 
Ghosh S et al. Interleukin-11 reduces TLR4-induced colitis in 
TLR2-deficient mice and restores intestinal STAT3 signaling. 
Gastroenterology 2010; 139: 1277-88. 
[304] Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized, double 
blind controlled trial of subcutaneous recombinant human 
interleukin-11 versus prednisolone in active Crohn's disease. Am J 
Gastroenterol 2006; 101: 793-7. 
[305] Pena RC, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, 
Graffner H. Interferon beta-1a for the maintenance of remission in 
patients with Crohn's disease: results of a phase II dose-finding 
study. BMC Gastroenterol 2009; 9: 22. 
[306] Pena-Rossi C, Schreiber S, Golubovic G, et al. Clinical trial: a 
multicentre, randomized, double-blind, placebo-controlled, dose-
finding, phase II study of subcutaneous interferon-beta-la in 
moderately active ulcerative colitis. Aliment Pharmacol Ther 2008; 
28: 758-67. 
[307] Neurath MF, Travis SP. Mucosal healing in inflammatory bowel 
diseases: a systematic review. Gut 2012; 61: 1619-35. 
[308] Sturm A, Dignass AU. Epithelial restitution and wound healing in 
inflammatory bowel disease. World J Gastroenterol 2008; 14: 348-
53. 
[309] Kara E, Sungurtekin H, Sungurtekin U, Alkanat M, Ilkgul O. The 
effect of recombinant human growth hormone (rhGH) on 
trinitrobenzene sulfonic acid-induced colitis in rats: an 
experimental study. Inflamm Bowel Dis 2004; 10: 112-5. 
[310] Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, 
McKinley MJ. A preliminary study of growth hormone therapy for 
Crohn's disease. N Engl J Med 2000; 342: 1633-7. 
[311] Procaccino F, Reinshagen M, Hoffmann P, et al. Protective effect 
of epidermal growth factor in an experimental model of colitis in 
rats. Gastroenterology 1994; 107: 12-7. 
[312] Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. 
Epidermal growth factor enemas with oral mesalamine for mild-to-
moderate left-sided ulcerative colitis or proctitis. N Engl J Med 
2003; 349: 350-7. 
[313] Bajaj-Elliott M, Breese E, Poulsom R, Fairclough PD, MacDonald 
TT. Keratinocyte growth factor in inflammatory bowel disease. 
Increased mRNA transcripts in ulcerative colitis compared with 
Crohn's disease in biopsies and isolated mucosal myofibroblasts. 
Am J Pathol 1997; 151: 1469-76. 
[314] Egger B, Procaccino F, Sarosi I, Tolmos J, Buchler MW, Eysselein 
VE. Keratinocyte growth factor ameliorates dextran sodium sulfate 
colitis in mice. Dig Dis Sci 1999; 44: 836-44. 
[315] Miceli R, Hubert M, Santiago G, et al. Efficacy of keratinocyte 
growth factor-2 in dextran sulfate sodium-induced murine colitis. J 
Pharmacol Exp Ther 1999; 290: 464-71. 
[316] Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin (keratinocyte 
growth factor-2) for the treatment of active ulcerative colitis: a 
randomized, double-blind, placebo-controlled, dose-escalation trial. 
Aliment Pharmacol Ther 2003; 17: 1355-64. 
[317] Babyatsky MW, Rossiter G, Podolsky DK. Expression of 
transforming growth factors alpha and beta in colonic mucosa in 
inflammatory bowel disease. Gastroenterology 1996; 110: 975-84. 
[318] Maric I, Poljak L, Zoricic S, et al. Bone morphogenetic protein-7 
reduces the severity of colon tissue damage and accelerates the 
healing of inflammatory bowel disease in rats. J Cell Physiol 2003; 
196: 258-64. 
[319] Tolstanova G, Khomenko T, Deng X, et al. Neutralizing anti-
vascular endothelial growth factor (VEGF) antibody reduces 
severity of experimental ulcerative colitis in rats: direct evidence 
for the pathogenic role of VEGF. J Pharmacol Exp Ther 2009; 328: 
749-57. 
[320] Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links 
angiogenesis and inflammation in inflammatory bowel disease 
pathogenesis. Gastroenterology 2009; 136: 585-95. 
[321] Deng X, Szabo S, Khomenko T, et al. Novel pharmacologic 
approaches to the prevention and treatment of ulcerative colitis. 
Curr Pharm Des 2013; 19: 17-28. 
[322] Tolstanova G, Deng X, Khomenko T, et al. Role of anti-angiogenic 
factor endostatin in the pathogenesis of experimental ulcerative 
colitis. Life Sci 2011; 88: 74-81. 
[323] Beck PL, Podolsky DK. Growth factors in inflammatory bowel 
disease. Inflamm Bowel Dis 1999; 5: 44-60. 
[324] Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer 
in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35. 
[325] Svrcek M, Cosnes J, Tiret E, Bennis M, Parc Y, Flejou JF. 
Expression of epidermal growth factor receptor (EGFR) is frequent 
in inflammatory bowel disease (IBD)-associated intestinal cancer. 
Virchows Arch 2007; 450: 243-4. 
[326] Dube PE, Yan F, Punit S, et al. Epidermal growth factor receptor 
inhibits colitis-associated cancer in mice. J Clin Invest 2012; 122: 
2780-92. 
[327] Clavel T, Haller D. Bacteria- and host-derived mechanisms to 
control intestinal epithelial cell homeostasis: implications for 
chronic inflammation. Inflamm Bowel Dis 2007; 13: 1153-64. 
[328] Barnich N, Carvalho FA, Glasser AL, et al. CEACAM6 acts as a 
receptor for adherent-invasive E. coli, supporting ileal mucosa 
colonization in Crohn disease. J Clin Invest 2007; 117: 1566-74. 
[329] Chamaillard M, Dessein R. Defensins couple dysbiosis to primary 
immunodeficiency in Crohn's disease. World J Gastroenterol 2011; 
17: 567-71. 
[330] Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome 
proliferator-activated receptor gamma activation is required for 
maintenance of innate antimicrobial immunity in the colon. Proc 
Natl Acad Sci USA 2010; 107: 8772-7. 
[331] Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active 
ulcerative colitis: a randomized placebo-controlled trial. 
Gastroenterology 2008; 134: 688-95. 
[332] Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: 
Implications for therapeutic applications in inflammatory bowel 
diseases. Inflamm Bowel Dis 2008; 14: 1585-96. 
[333] Grabig A, Paclik D, Guzy C, et al. Escherichia coli strain Nissle 
1917 ameliorates experimental colitis via toll-like receptor 2- and 
toll-like receptor 4-dependent pathways. Infect Immun 2006; 74: 
4075-82. 
[334] Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, 
double-blind, placebo-controlled trial of fructo-oligosaccharides in 
active Crohn's disease. Gut 2011; 60: 923-9. 
[335] Meijer BJ, Dieleman LA. Probiotics in the treatment of human 
inflammatory bowel diseases: update 2011. J Clin Gastroenterol 
2011; 45 (Suppl): 139-44. 
[336] Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. 
Ineffectiveness of probiotics in preventing recurrence after curative 
resection for Crohn's disease: a randomised controlled trial with 
Lactobacillus GG. Gut 2002; 51: 405-9. 
[337] Mack DR. Probiotics in inflammatory bowel diseases and 
associated conditions. Nutrients 2011; 3: 245-64. 
Gut Inflammation: Current Update on Pathophysiology Current Pharmaceutical Design, 2014, Vol. 20, No. 00    19 
[338] Anderson JL, Edney RJ, Whelan K. Systematic review: faecal 
microbiota transplantation in the management of inflammatory 
bowel disease. Aliment Pharmacol Ther 2012; 36: 503-16. 
[339] Summers RW, Elliott DE, Urban JF, Jr., Thompson RA, Weinstock 
JV. Trichuris suis therapy for active ulcerative colitis: a 
randomized controlled trial. Gastroenterology 2005; 128: 825-32. 
[340] Summers RW, Elliott DE, Urban JF, Jr., Thompson R, Weinstock 
JV. Trichuris suis therapy in Crohn's disease. Gut 2005; 54:87-90. 
[341] Motomura Y, Wang H, Deng Y, El-Sharkawy RT, Verdu EF, Khan 
WI. Helminth antigen-based strategy to ameliorate inflammation in 
an experimental model of colitis. Clin Exp Immunol 2009; 155: 88-
95. 
[342] Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell 
immunoregulation varies in early and late inflammatory bowel dis-
ease. Gut 2007; 56: 1696-705. 
 
 
Received: April 12, 2013             Accepted: June 7, 2013 
